# Microcap Research — full report text > Free, independent deep-dive equity research on Canadian nano- and microcap public companies. Institutional-quality analysis for individual investors — no paywall. Source: https://microcapresearch.ca Generated: 2026-08-28T00:42:27.105Z Reports: 12 Free to cite with attribution to "Microcap Research (https://microcapresearch.ca)". Not investment advice — see https://microcapresearch.ca/disclosures. --- # IC Group Holdings Inc. (TSXV: ICGH) — Equity Research - URL: https://microcapresearch.ca/reports/icgh-ic-group-holdings-inc-2026-q2update - PDF: https://microcapresearch.ca/reports/icgh-ic-group-holdings-inc-2026-q2update.pdf - Report ID: ICGH-2026-08-Q2update - Published: 2026-08-27 - Sector: Marketing Technology - Rating: Spec. Buy - Price target: C$1.10 - Price at publication: C$0.42 - Implied upside: +162% - Market cap: C$17.3M - Status: CURRENT **Bottom line:** Microcap Research rates IC Group Holdings Inc. (TSXV: ICGH) Spec. Buy with a 12-month price target of C$1.10, about 162% above the C$0.42 share price at publication on Aug 27, 2026. Market capitalisation at publication: C$17.3M. **Thesis:** Q2 revenue grew 26% with 97% organic growth, but gross profit rose only 15% and IC Mobile — the largest segment — added C$0.8M of revenue while subtracting C$0.32M of gross profit. Adjusted EBITDA of C$0.67M was flat sequentially and is roughly C$0.43M ex-FX. The stock at C$0.42 is now ~0.77x LTM revenue, cheaper than at initiation. Maintain Spec. Buy, C$1.10. ## Key statistics - Market Cap: C$17.3M - EV/Revenue (LTM): ~0.77x - EV/Adj. EBITDA (LTM): ~9.8x - Revenue (Q2 2026): C$8.17M (+26%) - Adj. EBITDA (Q2 2026): C$0.67M (C$0.43M ex-FX) - Gross Margin (Q2 2026): 42% ## Update Summary This update follows IC Group's Q2 2026 results (three and six months ended June 30, 2026), released August 26, 2026, and the August 27 investor webinar. We maintain our Speculative Buy rating and maintain our 12-month price target of C$1.10, representing approximately 162% upside from C$0.42 (as of 2026-08-27). Revenue grew 26% to C$8.2M with 97% of the growth organic, but consolidated gross profit rose only 15% — IC Mobile, the largest segment, delivered a 25% revenue increase and negative C$0.32M of incremental gross profit. Adjusted EBITDA of C$0.67M was flat sequentially and, adjusted for a C$0.24M foreign-exchange gain and a C$0.27M insurance profit-commission timing shift, materially thinner than the headline 345% growth implies. Our initial coverage on ICGH was published May 7, 2026, followed by a Q1 update on May 28, 2026. The thesis frames IC Group as a sub-1x-revenue MarTech compounder with Tier-1 Canadian messaging infrastructure, a scaling sports-tech SaaS platform (Fannex), and a high-margin specialty insurance book. Q2 is the second print since initiation and it sharpens, rather than resolves, the central question: whether 25%+ top-line growth converts to durable gross profit given the segment mix. ## What Changed - Revenue: +26% YoY to C$8.2M (H1: +27% to C$15.9M), with approximately 97% of Q2 growth organic — the cleanest organic read since initiation. Sequential growth was +5% versus Q1's C$7.8M. - Gross profit lagged badly: +15% to C$3.4M against +26% revenue, with consolidated gross margin down to 42% from 46%. All C$0.44M of the incremental gross profit came from IC Engage (+C$0.46M) and IC Insurance (+C$0.30M); IC Mobile subtracted C$0.32M. - Adjusted EBITDA quality: C$0.67M, up 345% YoY but unchanged sequentially, breaking the four-quarter sequential improvement streak management highlighted in Q1. Q2 other income of C$0.24M was described as comprised entirely of FX gains and is not added back in the reconciliation; the prior-year quarter carried a C$0.15M FX loss. Normalising both periods for FX, Adjusted EBITDA is roughly C$0.43M versus C$0.30M — call it +45%, not +345%. Management was candid on the call, with the CFO stating the 345% figure is "more a function of the base we were measuring that against a year ago." - Segment Adjusted EBITDA disclosed for the first time: IC Engage C$1.154M (+385%), IC Mobile C$(0.19)M (versus +C$0.14M), IC Insurance approximately C$0.23M. Backing into the consolidated figure implies roughly C$(0.52)M per quarter of unallocated corporate drag , or about C$2.1M annualised — the operating segments generated approximately C$1.19M in aggregate and corporate consumed 44% of it. - IC Mobile deterioration: revenue +25% to C$3.9M (fully organic), but gross margin fell to 10% from 22%, and gross profit dropped 46% to C$0.38M. Segment gross margin has now stepped down two consecutive quarters (22% → 17% → 10%). Causes cited: wholesale mix shift, carrier price increases in fiscal 2025 and again in April 2026 not fully passed through, gateway overage fees, and double-running platform costs during migration. - IC Insurance inflected, but on timing: revenue +147% to C$0.90M and first segment operating income of C$0.13M. Management disclosed the split on the call: approximately C$263K from recurring underwriting growth (organic plus the October 2025 Players Health portfolio) and C$275K from the annual profit commission , which was recognised in Q2 this year versus Q4 last year. Net of the commission the segment was roughly breakeven, and Q4 2026 now faces a tougher comparison. - IC Engage carried the quarter: revenue +12% to C$3.3M with gross margin expanding to 75% from 69% on better internal utilisation and reduced third-party fulfillment. Segment operating income +240%. Revenue was down 10% sequentially, attributed to client annual-planning seasonality. Note that C$0.237M of the segment's FX gain sits inside its Adjusted EBITDA; ex-FX the segment's growth is closer to +142% than +385%. - Cash and working capital: cash fell to C$2.33M from C$4.81M at year-end. H1 operating cash flow was C$(1.38)M, though before working-capital movements operations generated +C$0.77M versus a C$0.26M use a year earlier. Deferred revenue drew down from C$2.70M (December) to C$1.60M (March) to C$1.05M (June) — two consecutive quarters, and a forward-book item to watch. Negative working capital improved to C$(0.78)M from C$(3.2)M a year ago. - New contracts (all post-quarter in effect): an exclusive three-year partnership with an unnamed global venue technology provider (effective June 19, announced July 23) with no minimum revenue commitments; a renewal and expansion with a longstanding Fortune 50 technology client spanning 30 countries (June 30, announced July 8); and an enterprise messaging agreement now quantified at up to 120 million messages of throughput and up to C$1M of incremental ARR . None contributed to Q2. - Bullet Messaging: subsequent to quarter-end, IC Group entered a convertible promissory note for up to C$500K (C$187.5K funded through August), convertible into a 15% equity interest by December 31, 2027. Management confirmed on the call that Bullet is the partner for the mobile gateway migration and that post-migration the company will own "a state-of-the-art system that we have an ownership stake in." - Capital structure: bank debt reduced C$0.80M in H1 to C$6.92M; no new borrowings. 530,433 options were granted June 29 at a C$0.45 strike to settle 2025 executive bonuses — cash-conserving, but a market-implied valuation marker. Shares outstanding 41,290,567. Insiders hold approximately 53%. ## Thesis Check Reviewing each of the five original pillars: - Pillar 1 — Exceptional Organic Growth at Scale (INTACT): +26% revenue with 97% organic is the highest organic proportion since initiation, and LTM revenue reached approximately C$30.7M. The qualifier is that growth is no longer converting proportionally: gross profit grew 15% against 26% revenue, and Adjusted EBITDA was flat sequentially. The engine runs; the transmission is slipping. - Pillar 2 — IC Mobile: Defensible Tier-1 Infrastructure (WEAKENED): We flagged margin as the watch item last quarter and it deteriorated further, from 17% to 10%, with segment Adjusted EBITDA turning negative. The competitive position — one of three Tier-1 Canadian aggregators with direct carrier connections and full domestic data sovereignty — is unchanged and remains genuinely defensible. What has weakened is the economics: at roughly 80% of revenue consumed by carrier and system costs, this is a thin-spread business whose growth currently dilutes consolidated margin. Management targets a return to approximately 20% margin post-migration and claims the new platform brings "contracts that guarantee us pretty much a locked-in margin." That is a stronger forward statement than anything in the filings and is unverifiable until Q3/Q4 print. We downgrade this pillar and will not restore it without two quarters of margin evidence. - Pillar 3 — Fannex: A SaaS Platform at Inflection (STRENGTHENED): IC Engage posted a 75% gross margin, 23% gross profit growth, 240% operating income growth, and the first disclosed segment Adjusted EBITDA of C$1.154M. The exclusive three-year venue technology partnership adds a distribution channel into community, educational and sports venues, and the June live-event initiative spanned 78 events across 15 teams reaching over 400,000 fans. This remains the pillar carrying the thesis. - Pillar 4 — Deeply Discounted Valuation (STRENGTHENED): The dislocation widened again. At C$0.42 the enterprise value is approximately C$23.5M against LTM revenue of approximately C$30.7M — roughly 0.77x , down from approximately 0.85x at the Q1 update and approximately 0.94x at initiation. The market is now paying less for a business that has grown revenue 26% and turned three consecutive quarters of positive Adjusted EBITDA. - Pillar 5 — Multiple Near-Term Catalysts (INTACT): The catalyst set is now denser and more datable: gateway migration completion targeted for end of Q3, the venue technology partnership ramp, the Fortune 50 renewal delivering through fiscal 2026–2027, up to C$1M of new messaging ARR, and the senior lender renewal in the fall. The offsetting item is that the insurance profit commission will not repeat in Q4. ## Updated Financials | Metric | Q2 2025 | Q2 2026 | YoY Change | | Revenue (C$M) | $6.49M | $8.17M | +26% | | Gross Profit (C$M) | $3.00M | $3.44M | +15% | | Gross Margin | 46% | 42% | -4 pts | | Adj. EBITDA (C$M) | $0.15M | $0.67M | +345% | | Adj. EBITDA ex-FX (C$M) | $0.30M | $0.43M | ~+45% | | Net Loss (C$M) | $(0.58)M | $(0.11)M | improved | | ARR (% of revenue) | 70% | 67% | -3 pts | Segment revenue Q2 2026: IC Engage C$3.34M (+12%), IC Mobile C$3.93M (+25%), IC Insurance C$0.90M (+147%). Segment gross margin: 75%, 10% and 62% respectively. Adjusted EBITDA ex-FX is our own normalisation, not a company-reported figure; the company does not add back foreign-exchange gains in its reconciliation. We note the ARR metric requires care. Management disclosed recurring revenue by segment on the call — IC Mobile above 95%, IC Engage approximately 50%+, IC Insurance approximately 10% historically. Because IC Mobile is roughly half of revenue and almost entirely recurring, the blended 67–68% ARR figure is disproportionately composed of the lowest-margin, highest-variable-cost revenue in the group. We therefore assign less weight to ARR as a quality proxy than we did at initiation. ## Updated Valuation Our valuation framework is unchanged: EV/Revenue against MarTech and CPaaS peers trading at 1.5x–4x trailing revenue. We also maintain our forward FY2026 revenue estimate of approximately C$32.5M — H1 delivered C$15.9M, or 49% of the estimate, and IC Engage carries winter-sports seasonality that skews to H2, so the estimate remains achievable without heroic assumptions. In the interest of transparency: net debt has risen to approximately C$6.2M (cash of C$2.33M against bank debt of C$6.92M, debentures of C$1.31M, shareholder advances of C$0.23M and notes of C$0.04M) from approximately C$5.5M at the Q1 update, reflecting the H1 cash drawdown. Mechanically, applying our unchanged 1.5x base multiple to C$32.5M across 41.29M shares now yields approximately C$1.03 rather than C$1.10. We are maintaining the C$1.10 target on the basis that the difference falls within rounding tolerance for a speculative microcap and that management guided to a Q3 cash replenishment which reverses part of the net-debt increase. Readers should treat the base case as a C$1.03–C$1.10 band rather than a point estimate. | Scenario | EV Multiple (fwd Rev) | Price / Share | vs. Current | | Bear Case | 1.0x EV/Rev | C$0.64 | +52% | | Base Case | 1.5x EV/Rev | C$1.03–1.10 | +145% to +162% | | Bull Case | 2.0x EV/Rev | C$1.42 | +238% | Based on forward FY2026 revenue of C$32.5M, net debt of approximately C$6.2M, and 41,290,567 shares outstanding. On an LTM basis at C$0.42, ICGH trades at approximately 0.77x EV/Revenue and approximately 9.8x EV/Adj. EBITDA. ## Risk Update - Covenant Breach and Forbearance Expiry (HIGH, elevated): This is now the primary overhang. The company was in violation of both its maximum debt-to-EBITDA and minimum fixed-charge coverage covenants at the January 1, 2026 testing date. The senior lender's December 29, 2025 letter confirms it will not demand repayment or enforce remedies before January 1, 2027 solely on account of that breach. A breach at the January 1, 2027 test makes all senior debt due on demand. The CFO acknowledged the position openly on the call. Covenant tests are calculated on reported, not adjusted, EBITDA — and reported H1 EBITDA was C$0.91M. - November 30 Term Loan — Structure Requires Clarification (MEDIUM, new): The MD&A describes a C$5.2M term loan "maturing November 30, 2026." On the call the CFO characterised it differently, as a three-year fixed-rate tranche with "an interest rate maturity in November." These are not the same instrument profile: one is a principal repayment against C$2.33M of unrestricted cash, the other a repricing negotiation. Management stated renewal discussions with the senior lender are in process and progressing well, and total long-term debt is expected to amortise to approximately C$7.7M by year-end — roughly 3x management's stated approximately C$2.5M annualised run-rate Adjusted EBITDA, a defensible leverage level. We consider routine renewal the likely outcome but flag the disclosure inconsistency as unresolved. - IC Mobile Margin Recovery Depends on a Funded Counterparty (MEDIUM, new): The path back to approximately 20% segment gross margin runs through a gateway migration targeted for completion by end of Q3, executed with Bullet Messaging — the same private entity IC Group is financing via a C$500K convertible note with a 15% equity conversion option. Management frames this as strategic control over critical infrastructure, and owning a stake in one's platform provider is defensible. The counterpoint is concentration: if the migration slips, IC Group is a creditor to the reason it slipped. Both readings are legitimate; the dependency is real either way. - Gross Margin Compression (MEDIUM, worsening): The risk we flagged at initiation and again at Q1 has intensified. Consolidated gross margin is now 42%, down from 46%, driven by IC Mobile at 10%. If IC Mobile continues growing 25% at low-teens margins, revenue growth will keep diluting consolidated economics regardless of IC Engage's performance. - Q4 Comparison Difficulty (LOW, new): The C$275K insurance annual profit commission was recognised in Q2 2026 versus Q4 2025. Q4 2026 loses that contribution against a prior-year quarter that contained it. - Deferred Revenue Drawdown (LOW to MEDIUM, monitoring): Deferred revenue has declined two consecutive quarters to C$1.05M. Management attributes the sequential IC Engage softness to client annual-planning cycles and points to a post-quarter mandate renewal. Plausible, but Q3 will distinguish timing from a softer forward book. - Illiquidity / Small-Cap Risk (HIGH, unchanged): Approximately C$17M market cap, no formal sell-side coverage, thin TSXV volume, and insider ownership of approximately 53% leaving a genuinely narrow float. Not suitable for large positions. ## Conclusion Q2 was a quarter of divergence. IC Engage delivered exactly what the thesis requires — 75% gross margin, 240% operating income growth, and a distribution partnership plus a Fortune 50 renewal that land in H2 and 2027. IC Mobile did the opposite, growing revenue 25% while destroying C$0.32M of gross profit and turning segment Adjusted EBITDA negative. Consolidated Adjusted EBITDA of C$0.67M was flat sequentially and, once foreign-exchange gains and the insurance commission timing shift are stripped out, materially thinner than the 345% headline. Management deserves credit for saying so themselves on the call rather than hiding behind the number. The thesis is not broken, but it is now more concentrated than we underwrote. Three of five pillars strengthened or held; the IC Mobile economics pillar weakened and its repair depends on a Q3 platform migration executed through a partner IC Group is financing. Behind that sits the January 1, 2027 covenant test, which is the genuine binding constraint on this equity — not the November loan event, which management appears well positioned to renew. At C$0.42 per share and a market capitalisation of approximately C$17.3M, ICGH trades at roughly 0.77x LTM revenue — cheaper than at our Q1 update and cheaper than at initiation, despite three consecutive quarters of positive Adjusted EBITDA and a widening organic growth profile. The Tier-1 messaging licence, the Lloyd's Coverholder authority, the 100-plus team live-event footprint and the new venue distribution channel remain ascribed essentially no value. We maintain our Speculative Buy rating with a C$1.10 price target, and we will treat Q3 gross margin in IC Mobile as the single most important datapoint for whether this rating survives into 2027. --- # Yangaroo Inc. (TSXV: YOO) — Equity Research - URL: https://microcapresearch.ca/reports/yoo-yangaroo-inc-2026 - PDF: https://microcapresearch.ca/reports/yoo-yangaroo-inc-2026.pdf - Report ID: YOO-2026-08 - Published: 2026-08-25 - Sector: Technology / Media Workflow Software - Rating: Spec. Buy - Price target: C$0.13 - Price at publication: C$0.06 - Implied upside: 117% - Market cap: C$3.81M - Status: CURRENT **Bottom line:** Microcap Research rates Yangaroo Inc. (TSXV: YOO) Spec. Buy with a 12-month price target of C$0.13, about 117% above the C$0.06 share price at publication on Aug 25, 2026. Market capitalisation at publication: C$3.81M. **Thesis:** Sixteen straight quarters of positive Normalized EBITDA — and Q2 2026 was the best yet: revenue +31% to US$2.16M, Normalized EBITDA +217% to US$699K at a 32.3% margin. Total liabilities are down 32% year over year with almost no dilution, and the CEO is taking salary in stock at C$0.03–0.04. Yet the shares trade at ~2.8x LTM EBITDA and a 57% cash-flow yield because a US$584K term loan matures December 31, 2026. ## Key statistics - Market Cap: C$3.81M - EV/Normalized EBITDA (LTM): ~2.8x - EV/Revenue (LTM): ~0.62x - Revenue (Q2 2026): US$2.16M (+31%) - Normalized EBITDA (LTM): US$1.70M - Op. Cash Flow Yield (LTM): ~57% ## Executive Summary Yangaroo Inc. (TSXV: YOO) is a Toronto-based media-workflow software company whose patented Digital Media Distribution System ("DMDS") moves advertising spots, traffic instructions, music tracks, and music videos between brands, agencies, labels, and a broad network of North American broadcasters, CTV/OTT services, and digital publishers. Alongside distribution it sells broadcast clearance, closed captioning, campaign trafficking, analytics, and a market-leading awards-show submission and judging platform. The company reports in US dollars and has been listed since 1999. On August 25, 2026, Yangaroo reported its sixteenth consecutive quarter of positive Normalized EBITDA — and by some margin its best. Q2 2026 revenue rose 31% year over year to US$2.16M, Normalized EBITDA rose 217% to US$699K (a 32.3% margin), and the quarter produced US$354K of net income against a US$281K loss a year earlier. On a trailing-twelve-month basis the business now generates US$7.57M of revenue, US$1.70M of Normalized EBITDA, and US$1.58M of operating cash flow. The equity is capitalized at C$3.81M. We initiate coverage with a Spec. Buy rating and a 12-month price target of C$0.13, representing approximately 117% upside from C$0.06 (last trade August 24, 2026, per stockanalysis.com / S&P Global Market Intelligence). At an enterprise value of roughly C$6.5M, YOO trades at ~2.8x LTM Normalized EBITDA and ~0.62x LTM revenue, with trailing operating cash flow equal to 57% of the market capitalization. The offset is real and specific: a US$584K term loan matures December 31, 2026, going-concern language remains in the financial statements, and 2026 is a peak comparison year. We think the cash generation now on display is sufficient to clear the debt wall, and that the market is pricing a solvency question that the Q2 numbers have largely answered. ## Company Overview Yangaroo runs a single technology platform across two reporting divisions. Both are software-and-services hybrids: the platform carries the file, and human specialists handle the parts of the workflow — clearance substantiation, captioning, quality control — that clients will not or cannot automate. That mix caps gross margin below pure-SaaS levels but makes the company far harder to displace once embedded in an agency's traffic desk. - Advertising (US$5.27M FY2025 revenue, 74% of total): Ad-spot delivery and campaign trafficking to linear TV, radio, CTV/OTT, and digital destinations, plus broadcast clearance in both the United States and Canada, closed captioning, long-form digitization, syndication, and campaign analytics. Q2 2026 revenue of US$1.62M was up 38% year over year. This is the growth engine and the division absorbing the company's incremental headcount spend. - Entertainment — Music & Awards (US$1.84M FY2025 revenue, 26% of total): Music track and music-video promotion and delivery for major labels and independents, and the Yangaroo Awards v3 platform handling submissions, judging, and program administration for major award shows — increasingly extended into fan voting. Q2 2026 revenue of US$546K was up 14%, with two new fan-vote programs onboarded in the quarter. Awards revenue is contracted, multi-year, and highly recurring. As at June 30, 2026 the company had 63,576,462 common shares outstanding, no warrants and no stock options, 4,560,000 RSUs, and 400,000 DSUs. Concurrent with the Q2 release the company disclosed the issuance of a further 243,657 shares to the CEO under the Shares for Services Arrangement covering April through July 2026, taking the count to approximately 63.82 million. Insiders hold roughly 19% of the shares; the float is approximately 51.2 million shares. ## Investment Thesis — Five Pillars ### 1. Sixteen Consecutive Quarters of Positive Normalized EBITDA, and Q2 2026 Was the Best of Them Yangaroo has now posted positive Normalized EBITDA in every quarter since Q3 2022. That is not a turnaround narrative in progress; it is four years of realized operating discipline in a business the market values at less than four million Canadian dollars. The Q2 2026 print was the strongest quarter in the streak: US$699,347 of Normalized EBITDA on US$2,162,823 of revenue, a 32.3% margin, versus US$220,909 and a 13.4% margin in Q2 2025. The mechanism behind the jump is the part worth underwriting. Q2 revenue grew US$511,382 while total operating expenses grew only US$71,520 — a 4% increase against a 31% revenue increase. Over the full first half, revenue rose US$462,328 (13%) while operating expenses rose US$49,119 (1%). General and administrative costs actually fell 33% year over year in H1 as the long-running DMDS lawsuit settled in Q4 2025 and bad-debt allowances shrank on improved collections. This is a fixed-cost platform business finally getting revenue growth on top of a cost base that management has held flat for two years, and the incremental margin flows through almost entirely. The quarterly Normalized EBITDA record, in US dollars: | Fiscal Year | Q1 | Q2 | Q3 | Q4 | | 2026 | $257,606 | $699,347 | — | — | | 2025 | $264,251 | $220,909 | $152,906 | $589,541 | | 2024 | $237,581 | $337,818 | $466,458 | $540,504 | | 2023 | $116,293 | $541,952 | $266,269 | $211,061 | Normalized EBITDA is a non-IFRS measure as defined by the company: EBITDA adjusted for share-based compensation, restructuring, foreign exchange, remeasurement of contingent consideration and the embedded derivative, acquisition fees, one-time credits, and settlement gains. ### 2. The Balance Sheet Repaired Itself in Eighteen Months The single most under-appreciated fact about Yangaroo is how far the capital structure has moved without a dilutive financing. Total liabilities fell from US$4,066,726 at June 30, 2025 to US$2,767,083 at June 30, 2026 — a 32% reduction in twelve months. Shareholders' equity nearly tripled over the same span, from US$675,993 to US$1,861,229. The working capital deficiency narrowed from US$2,140,887 to US$753,376. Share count went from 63,137,490 to 63,576,462, an increase of less than 0.7%, entirely from a shares-for-services arrangement with the CEO. That arrangement deserves a second look, because it cuts against the usual microcap pattern. Under it, CEO Grant Schuetrumpf has taken a cumulative 882,979 shares in lieu of cash compensation for the months of January 2025 through July 2026 — including 243,657 shares disclosed alongside the Q2 release at issue prices of C$0.03 to C$0.04 per share. The chief executive has been accepting stock at roughly half the current market price rather than drawing cash from a company with US$191,387 on the balance sheet. It is a small number in dollar terms and it is dilution, but it is dilution that conserves cash and aligns the operator with the outcome at prices well below where the stock trades today. The deleveraging is being funded by operations. The term loan balance fell from US$1,159,680 at December 31, 2024 to US$827,571 at December 31, 2025 to US$584,049 at June 30, 2026 — US$237,273 of principal repaid in the first half of 2026 alone. Trailing operating cash flow of approximately US$1.58M against remaining debt (revolver, term loan, and convertible debenture host) of roughly US$1.79M means the company can now theoretically extinguish its entire funded debt load inside fourteen months of cash generation. The accumulated deficit of US$33.2M is worth noting for a different reason: it is a legacy of the pre-2022 company, and it means Yangaroo carries substantial tax attributes. Cash taxes in the first half of 2026 were US$16,945 on US$408,196 of pre-tax income. ### 3. Broadcast Clearance Is the Structural Growth Story — the Election Is the Cyclical One It would be easy to read the 38% Advertising growth as a pure political-advertising and FIFA World Cup windfall, and management is candid that both contributed materially. But the more durable driver is the deliberate build-out of broadcast clearance capability in both the United States and Canada, which the company has been funding through the P&L — the increase in salaries and consulting expense in Q2 and H1 was explicitly attributed to clearance headcount. Clearance matters strategically because it is the workflow step that sits before distribution. Every advertisement destined for broadcast requires substantiation and regulatory sign-off; the client who uses Yangaroo for clearance has a strong reason to use Yangaroo for trafficking, captioning, and delivery. In November 2025 the company launched Canadian preclearance services under an industry veteran hire, and it has been advancing its role in Canadian broadcast regulatory workflows. Management frames the objective plainly: become more deeply embedded in client operations and create additional recurring revenue. The Entertainment division supplies the same kind of stickiness at smaller scale. Awards revenue runs on long-standing multi-year relationships, and the fan-voting extension — two new programs onboarded in Q2 alone — is the company monetizing an installed base rather than chasing new logos. Meanwhile a major broadcaster's return to music-video programming has reopened a video-distribution revenue line that had been shrinking since 2024. ### 4. 2.8x EBITDA, 0.62x Revenue, and a 57% Cash-Flow Yield With Zero Analyst Coverage At C$0.06 and 63.58 million shares, the equity is worth C$3.81M (US$2.75M at ~1.385 USD/CAD). Net debt at June 30, 2026 — revolver, term loan, convertible debenture, embedded derivative, and lease obligations less cash — was US$1.95M. Enterprise value is therefore approximately US$4.70M, or C$6.5M. | Multiple (LTM, to Q2 2026) | Value | Implied Metric | | EV / Revenue | ~0.62x | US$7.57M revenue | | EV / Normalized EBITDA | ~2.8x | US$1.70M Normalized EBITDA | | P / E | ~2.4x | US$1.13M net income | | Operating Cash Flow Yield | ~57% | US$1.58M operating cash flow | Small-cap media-workflow and marketing-technology comparables in Canada typically clear 5–8x EBITDA even without growth; larger martech platforms trade well into double digits. Yangaroo at 2.8x is not being valued as a slow-growth software business — it is being valued as a going-concern risk. There is no sell-side coverage, average twenty-day volume is roughly 85,000 shares, and the stock traded as low as C$0.02 in the last fifty-two weeks. This is a name where the discount is largely a function of who is not allowed to buy it. ### 5. The December 2026 Debt Wall Is the Catalyst, Not the Obituary The financial statements carry going-concern language, and the reason is narrow and specific: the ability to continue as a going concern depends on refinancing or repaying the US$584,049 term loan maturing December 31, 2026. That is the entire condition. It is not a cash-burn problem — the company generated US$391,251 of net income and US$711,920 of operating cash flow in the first half. Three things have moved in the company's favour. On March 23, 2026 the bank agreed to a fourth amendment extending both the credit facility and the term loan to December 31, 2026 and waiving covenant testing until that date, subject to quarterly minimum EBITDA targets — targets Q2's US$685K of reported EBITDA comfortably clears. On August 11, 2026 the company received a US$157,575 Employee Retention Tax Credit refund plus US$32,571 of interest, which it intends to apply against the credit facility; claims for two further quarters remain outstanding. And the term loan is amortizing on its own: at the H1 2026 repayment pace of roughly US$237K per half, the balance would be near US$350K by year-end without any refinancing at all. Resolution of the December maturity — through extension, refinancing, or repayment out of an unusually strong H2 — is the single clearest re-rating catalyst in the story. A company generating US$1.7M of trailing EBITDA does not typically get valued at 2.8x once the market stops asking whether it will exist. ## Financial Summary | Metric (US$) | FY2024 | FY2025 | LTM to Q2 2026 | | Revenue | $8.06M | $7.11M | $7.57M | | — Advertising | $5.98M | $5.27M | n/a | | — Entertainment | $2.08M | $1.84M | n/a | | Normalized EBITDA | $1.58M | $1.23M | $1.70M | | Normalized EBITDA Margin | 19.6% | 17.3% | 22.5% | | Net and Comprehensive Income | $0.54M | $0.33M | $1.13M | | Operating Cash Flow | $1.65M | $1.27M | $1.58M | | Balance Sheet (US$) | Jun 30, 2025 | Dec 31, 2025 | Jun 30, 2026 | | Cash | $271,234 | $161,112 | $191,387 | | Total Assets | $4,742,719 | $4,799,728 | $4,628,312 | | Total Liabilities | $4,066,726 | $3,360,240 | $2,767,083 | | Shareholders' Equity | $675,993 | $1,439,488 | $1,861,229 | | Working Capital (Deficiency) | ($2,140,887) | ($1,255,379) | ($753,376) | | Term Loan Balance | — | $827,571 | $584,049 | | Common Shares Outstanding | 63,137,490 | 63,320,275 | 63,576,462 | Source: Yangaroo Inc. Q2 2026 condensed interim financial statements, MD&A, and news release (all August 25, 2026), and FY2025 audited financial statements and MD&A (April 29, 2026). LTM figures are the sum of Q3 2025 through Q2 2026 as reported. ## Valuation We value Yangaroo on EV/Normalized EBITDA using mid-cycle rather than 2026 earnings. This is deliberate. Calendar 2026 carries two non-repeating tailwinds — US midterm elections in November and the FIFA World Cup — and management named both as material contributors to Q2's 38% Advertising growth. Applying a multiple to a peak-year number would produce a target the business cannot defend in 2027. Our base case therefore uses US$1.85M of sustainable Normalized EBITDA, above the FY2025 trough of US$1.23M and the FY2024 result of US$1.58M (reflecting the clearance build and the awards/fan-vote expansion) but below what we expect the company to actually earn this year. For reference, our estimate for full-year 2026 is revenue of approximately US$8.3–8.5M and Normalized EBITDA of approximately US$2.0–2.2M, against H1 actuals of US$3.90M and US$0.96M respectively, with Q3 and Q4 carrying the bulk of midterm political spend. Base and bull cases are struck on a fully diluted share count of approximately 73.5 million, reflecting the 4,560,000 RSUs, 400,000 DSUs, and the roughly 5.0 million shares issuable on conversion of the CAD $500,000 debentures at C$0.10. The bear case uses the basic count, since none of those instruments are in the money in that scenario. Net debt is stepped down in the base and bull cases to reflect continued amortization and application of ERTC proceeds; FX is taken at 1.385 USD/CAD. | Scenario | Basis | Price / Share | vs. Current | | Bear Case | 3.0x on US$1.3M mid-cycle Normalized EBITDA; 2027 political air pocket, no refinancing progress | C$0.042 | -30% | | Base Case | 4.5x on US$1.85M mid-cycle Normalized EBITDA; term loan resolved, clearance revenue sticks | C$0.134 | +123% | | Bull Case | 6.0x on US$2.3M Normalized EBITDA; clearance scales, debt cleared, multiple re-rates toward peers | C$0.246 | +310% | We round the base case to a 12-month price target of C$0.13 , implying 117% upside. It is worth stating plainly what that target represents: 4.5x EBITDA on a below-2026 earnings assumption. It is not an aggressive multiple. It is what a debt-free, cash-generative, twenty-five-year-old software business with 14% customer concentration should trade at once the balance-sheet question is off the table. ## Key Risks - Term Loan Maturity and Going-Concern Qualification (HIGH): The US$584,049 term loan matures December 31, 2026, and the credit facility is due on demand. The auditors' going-concern material uncertainty is tied directly to refinancing or repaying it. Management has extended twice; a third extension is not guaranteed, and failure would force an equity raise at a depressed price or an asset sale. - 2027 Political and Event Air Pocket (HIGH): US midterms and the FIFA World Cup are explicitly named drivers of 2026 growth. Neither recurs in 2027. Advertising revenue could revert toward the FY2025 run-rate of US$5.27M, and Normalized EBITDA toward US$1.3–1.5M. Investors buying on the Q2 headline should understand they are buying a cyclical peak quarter. - Nano-Cap Illiquidity (HIGH): Average twenty-day volume is roughly 85,000 shares against a C$3.81M market capitalization and a 51.2 million share float. The 52-week range is C$0.02 to C$0.08. Position sizing is a genuine constraint; exiting a meaningful position in a weak tape may not be possible at anything near the quoted bid. - Working Capital Deficiency (MEDIUM): Despite substantial improvement, current liabilities still exceed current assets by US$753,376, and cash on hand is only US$191,387. Total liquidity — cash plus undrawn revolver — was US$667,570 at quarter end. The company is dependent on continued positive operating cash flow and on the revolver not being called. - Dilution (MEDIUM): 4,560,000 RSUs and 400,000 DSUs are outstanding, with 2,060,000 RSUs granted in May 2026 vesting May 2027. The CAD $500,000 convertible debentures convert at C$0.10 into approximately 5.0 million shares and mature November 30, 2027. The Shares for Services Arrangement continues to issue stock monthly to the CEO — 882,979 shares cumulatively through July 2026 — and grinds the count higher, albeit slowly. Combined, roughly 16% dilution from the current base — material at this share count, and reflected in our base and bull cases. - Foreign Exchange (MEDIUM): The company reports in USD but carries a net CAD liability exposure of CAD $3,026,477, largely the revolver, term loan, and debentures. A 5% currency move swings profit or loss by US$106,484 — meaningful against US$391,251 of half-year net income, and a recurring source of noise in the reported (non-normalized) numbers. - Advertising Market Structure (MEDIUM): FY2025 revenue fell 12% on reduced discretionary marketing spend and a continued shift of media mix toward digital channels. That structural drift has not reversed; 2026 growth is masking it. Yangaroo's answer is clearance and integrated workflow, but the underlying linear-broadcast delivery volumes remain exposed. ## Conclusion Yangaroo is a twenty-five-year-old company that spent most of its life not working and has now spent four years working. Sixteen consecutive quarters of positive Normalized EBITDA, total liabilities down 32% year over year, equity nearly tripled, and a Q2 that generated a 32.3% Normalized EBITDA margin on 31% revenue growth — none of that is speculative. It is reported, audited in its annual form, and repeated across enough quarters to be a pattern rather than an accident. What is speculative is whether the last piece of the old balance sheet gets cleared. The going-concern language exists for one reason: a US$584,049 term loan due December 31, 2026. Against US$1.58M of trailing operating cash flow, a bank that has now amended three times, an amortization schedule that is retiring the balance on its own, and ERTC refunds being applied directly against the facility, we think the probability of resolution is high — but it is not certain, and a microcap with a demand revolver and US$191,387 of cash has no margin for a surprise. Investors should also be clear-eyed that 2026 is a peak comparison year and that 2027 will be harder. At C$0.06 per share and a C$3.81M market capitalization, Yangaroo trades at approximately 2.8x trailing Normalized EBITDA, 0.62x revenue, and a 57% operating cash flow yield — with no analyst coverage and no institutional ownership. The market is pricing a solvency question. The Q2 numbers are the beginning of the answer. We rate YOO Spec. Buy with a C$0.13 price target. --- # Innovotech Inc. (TSXV: IOT) — Equity Research - URL: https://microcapresearch.ca/reports/iot-innovotech-inc-2026-q2update - PDF: https://microcapresearch.ca/reports/iot-innovotech-inc-2026-q2update.pdf - Report ID: IOT-2026-08-Q2update - Published: 2026-08-19 - Sector: Life Sciences Services / Laboratory Testing - Rating: Hold - Price target: C$0.10 - Price at publication: C$0.08 - Implied upside: +25% - Market cap: C$4.36M - Status: CURRENT **Bottom line:** Microcap Research rates Innovotech Inc. (TSXV: IOT) Hold with a 12-month price target of C$0.10, about 25% above the C$0.08 share price at publication on Aug 19, 2026. Market capitalisation at publication: C$4.36M. **Thesis:** Q2 broke the thesis. Management confirmed the lost client program is permanent and that antimicrobial revenue is back at 2024 levels — reframing FY2025 as a peak, not a platform. Gross margin collapsed to 8.6% and cash fell 77% to C$374,671. The stock is 6% cheaper per share than at initiation but enterprise value is 29% higher. Downgrade to Hold, target C$0.10. ## Key statistics - Market Cap: C$4.36M - EV/Revenue (LTM): ~1.15x - Revenue (Q2 2026): C$0.68M (-31%) - Gross Margin (Q2 2026): 8.6% - Adj. EBITDAS (Q2 2026): C$(0.64)M - Cash (Jun 30, 2026): C$0.37M ## Update Summary This update follows Innovotech's Q2 2026 results, released after the close on August 18, 2026. We downgrade our rating from Spec. Buy to Hold and lower our 12-month price target to C$0.10 from C$0.18, representing approximately 25% upside from C$0.08 (last trade August 18, 2026, per Stockwatch). The quarter did not merely miss — it changed the shape of the thesis. Management confirmed the lost customer program is a permanent reduction rather than a pause, gross margin collapsed to 8.6%, and cash fell 77% from year-end to C$374,671. Most importantly, the valuation argument that anchored our initiation has partly closed on its own: enterprise value is now higher relative to revenue than when we initiated, because the balance sheet eroded faster than the share price did. Our initial coverage on IOT was published July 2, 2026 at C$0.085, framing Innovotech as a textbook microcap dislocation — a GMP-accredited lab-services platform that doubled revenue to C$4.53M and earned a profit in 2025, priced at ~0.73x EV/Revenue after a single client program ended and cratered Q1. The core question we posed was whether the Q1 stumble was survivable or terminal. Q2 answers a narrower version of that question: it is survivable, but the revenue base being defended is materially smaller than the FY2025 figure our target was struck against. ## What Changed - Revenue did not recover: Q2 revenue of C$679,841 fell 31% year over year from C$984,327, and H1 revenue of C$1,327,981 fell 38% from C$2,142,512. Revenue did rise modestly sequentially from Q1's C$648,140 — the only directional positive in the print. - The client loss is now permanent, by management's own admission: The MD&A states that after "discussions with the customer and observation of activity levels over an extended period, management concluded that the reduction in work from the client was likely to be a longer-term change rather than a temporary pause." This is the single most consequential sentence in the filing. At initiation we treated the Q1 revenue cliff as a stumble against a doubled base; management now treats it as the new baseline. - The FY2025 base is reframed as exceptional: Management discloses that Q2 2026 antimicrobial testing revenue of C$270,829 was "consistent with the C$268,277 reported in the second quarter of 2024," and that 2026 activity is "broadly comparable to pre-2025 activity levels." In other words, the 107% FY2025 revenue growth we underwrote was substantially one large program, and the business has reverted to its 2024 antimicrobial run-rate. - Gross margin collapsed: Q2 gross profit was C$58,130 on a 8.6% margin, versus 53.3% in Q2 2025 and 24.1% in Q1 2026. Cost of sales rose 35% year over year to C$621,711 on 31% lower revenue — the arithmetic of a fixed lab cost base running at low utilization. - Adj. EBITDAS loss more than doubled: C$(636,631) in Q2 versus C$(276,133) a year earlier, a -93.6% margin. H1 Adj. EBITDAS was C$(982,189). - The GMP/analytical line — our designated diversifier — also declined: C$320,871 in Q2, down 17% year over year, and down 14% on a H1 basis. At initiation we highlighted this line holding roughly flat while antimicrobial took the hit, and called it "the diversification engine of the thesis." It no longer held flat. - Balance sheet erosion is the headline: Cash fell from C$1,619,586 at December 31 to C$374,671. Working capital fell 67% from C$2,500,350 to C$834,318; the current ratio fell from 5.79 to 2.07. H1 consumed C$589,921 in operations and C$650,605 in investing. - Cost reset executed: Workforce reduced 20% versus end-Q1 staffing. Q2 G&A of C$543,231 was down 26% year over year, and R&D was cut 39%. Management expects these actions to "become more evident in operating results during the second half of 2026." - Business development spend went the other way, deliberately: Marketing and BD expense rose 305% in Q2 to C$121,945 and 379% in H1 to C$239,791 — the largest dedicated BD function in company history. - Keystone earnout reversed: A C$50,000 gain was recognized on remeasurement of contingent consideration from the November 2024 Keystone acquisition, because management concluded the post-acquisition performance milestones were "unlikely to be achieved." A cash-flow positive but strategically negative datapoint. - New commercial initiatives: InnovoTEST™ hazardous drug wipe testing kits launched August 13, 2026, targeting compounding pharmacies and hospitals against NAPRA environmental-monitoring guidance. The Company also quietly launched client consulting services (evidenced by a FendX release) and cites several clients advancing toward FDA 510(k) submissions. - Capital commitments taken on during a cash squeeze: Innovotech acquired a MALDI-TOF mass spectrometry system, a high-capacity autoclave, and expanded cleanroom infrastructure; PP&E rose 66% to C$1,492,190. The MALDI-TOF was subsequently sold and leased back in July (48 months at C$7,090/month), restoring roughly C$300K of working capital. Separately, the Company has signed a purchase agreement and paid a deposit on a permanent laboratory facility, with a condition-removal date of October 31, 2026 , subject to mortgage financing not yet secured. ## Thesis Check Reviewing each of the five original pillars, honestly: - Pillar 1 — The FY2025 Scale-Up Was Large, Real, and Profitable (BROKEN as a forward anchor): The FY2025 revenue of C$4.53M was real and audited, but management has now effectively disclosed that a large portion of it was a single program that is not returning, and that the underlying antimicrobial business is running at 2024 levels. A price target struck as a multiple of FY2025 revenue is a target struck against a number the business is not going to reproduce. This is the pillar that fails, and it is the reason the target moves as much as it does. - Pillar 2 — The Valuation Discounts a Permanent Impairment That the Balance Sheet Contradicts (BROKEN): The balance sheet no longer contradicts it. At initiation we cited C$1.32M cash, C$1.79M working capital and a 3.28x current ratio as the cushion that bought management time. Two quarters later that cushion is C$374,671 of cash, C$834,318 of working capital and a 2.07x current ratio. Worse, the arithmetic has inverted: enterprise value has risen to ~C$4.28M from ~C$3.31M at initiation even though the share price fell 6%, because C$945K of cash left the balance sheet. EV/Revenue on the trailing twelve months is now ~1.15x versus the ~0.73x we cited on FY2025. The stock is cheaper per share and more expensive per dollar of enterprise value. - Pillar 3 — Q1 Exposed the Concentration Risk But Also the Catalyst for Fixing It (INTACT, executing): This is the pillar that held. Management did exactly what the situation demanded — cut headcount 20%, reversed the "hold capacity for a return that isn't coming" error explicitly, tripled BD spend, and installed a CFO focused on cash discipline. New client relationships, renewed former-client outreach, and the inbound funnel from the redesigned website are all real. The caveat is that the GMP line we identified as the resilient half also declined 17%, so diversification is being built rather than merely revealed. - Pillar 4 — GLP Certification Is a Structural Market Expander (WEAKENED): GLP appears in the Q2 outlook only as "preparations toward Good Laboratory Practice (GLP) certification," bundled into a list of initiatives, with no timeline, no cost figure, and no progress milestone. At initiation we called the compliance drag "front-loaded and the option live." With R&D spend cut 36% in H1 and cash at C$375K, the option is still live but is now competing for capital it may not get on the original schedule. - Pillar 5 — Optionality: U.S. Capital-Markets Access, IP, and Owned Infrastructure (WEAKENED, and partly inverted): The OTCQB listing is done and InnovoTEST plus the new consulting line are genuine additions to the revenue surface. But two of the three original options have turned. The permanent-facility idea is no longer optionality — it is a signed purchase agreement with a deposit down and a hard October 31 condition-removal date, requiring mortgage financing from a company with C$375K of cash and a C$1.06M half-year loss. And InnovoSIL™, the silver IP platform, receives no update at all in a quarter where R&D was cut 39%. ## Updated Financials | Metric (C$) | Q2 2025 | Q1 2026 | Q2 2026 | YoY Change | | Revenue | 984,327 | 648,140 | 679,841 | -31% | | — Antimicrobial Testing | 521,616 | 302,073 | 270,829 | -48% | | — GMP / Analytical / Stability | 386,341 | 292,119 | 320,871 | -17% | | — Products (MBEC Assay®) | 76,370 | 53,948 | 88,141 | +15% | | Gross Profit | 524,354 | 155,941 | 58,130 | -89% | | Gross Margin | 53.3% | 24.1% | 8.6% | -44.7 pts | | Marketing & Bus. Development | 30,133 | 117,846 | 121,945 | +305% | | General & Administrative | 736,281 | 591,108 | 543,231 | -26% | | Adj. EBITDAS | (276,133) | (345,558) | (636,631) | -131% | | Net and Comprehensive Loss | (241,199) | (401,294) | (655,700) | -172% | Q1 2026 service-line figures are derived from reported H1 totals less Q2. Q1 2026 net loss was supported by C$192,294 of 2025 SR&ED tax incentive recognized in the quarter; Q2 includes a C$50,000 gain on reversal of the Keystone contingent consideration, which Adj. EBITDAS excludes. | Balance Sheet (C$) | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 | | Cash & Equivalents | 1,619,586 | ~1,320,000 | 374,671 | | Current Assets | 3,022,428 | — | 1,617,200 | | Current Liabilities | 522,078 | — | 782,882 | | Net Working Capital | 2,500,350 | 1,790,000 | 834,318 | | Current Ratio | 5.79x | 3.28x | 2.07x | | Property, Plant & Equipment | 897,931 | — | 1,492,190 | | Total Assets | 4,432,877 | ~4,300,000 | 3,585,017 | | Total Liabilities | 784,676 | ~1,050,000 | 993,810 | | Shareholders' Equity | 3,648,201 | — | 2,591,207 | | Net (Cash) Debt | (1,286,367) | — | (77,558) | | Common Shares Outstanding | 54,438,235 | 54,438,235 | 54,438,235 | Source: Innovotech Inc. Q2 2026 MD&A, interim consolidated financial statements and news release (all August 18, 2026), and Q1 2026 filings. Current liabilities at June 30 include C$214,272 of accounts payable relating to the MALDI-TOF system, which was sold and leased back in July 2026 and is replaced by a 48-month lease obligation at C$7,090 per month. Shares outstanding are unchanged; 1,900,000 stock options remain outstanding and there are no warrants. ## Updated Valuation Our framework — EV/Revenue, chosen at initiation because project-based volatility makes near-term earnings multiples meaningless — is unchanged. What changes is the revenue base we apply it to, and that change is the whole of the target reduction. At initiation we applied ~1.9x to FY2025 revenue of C$4.53M. That base is no longer defensible. Management has disclosed that 2026 antimicrobial activity is running at pre-2025 levels, and the Q2 print of C$270,829 versus Q2 2024's C$268,277 makes the point concretely. We therefore reset to a stabilized revenue base of approximately C$3.1M , built as follows: annualizing H1 2026 gives C$2.66M; the LTM figure is C$3.72M; we assume the 20% workforce reduction does not further impair delivery capacity, that GMP/analytical stabilizes near its Q2 run-rate, and that InnovoTEST, the consulting line, and the enlarged BD function contribute modestly from 2027. C$3.1M sits between the depressed H1 annualized figure and the trailing twelve months, and remains 32% below FY2025. We also raise the multiple applied to that base to ~1.75x from ~1.9x on a much larger number — reflecting that a smaller, less concentrated, cost-reset business with a genuine GMP franchise deserves a normal-ish services multiple, while the liquidity position and the unresolved facility financing warrant a discount to peers. Regulated CRO and analytical-testing comparables generally clear 1.5–2.5x sales; we are mid-range, not distressed. | Scenario | Basis | Price / Share | vs. Current | | Bear Case | 1.0x EV/Rev on C$2.7M; H2 burn continues, facility financing forces a dilutive raise | C$0.04 | -50% | | Base Case | 1.75x EV/Rev on C$3.1M stabilized revenue, less ~C$0.2M net debt | C$0.10 | +25% | | Bull Case | 2.5x EV/Rev on C$3.6M; BD pipeline converts, GLP lands, margin recovers on lower cost base | C$0.165 | +106% | Base and bull use 54,438,235 shares; the bear case assumes ~25% dilution from a financing at depressed prices. Shareholders' equity of C$2,591,207 equates to book value of approximately C$0.048 per share, which sits between the bear and base outcomes and is a reasonable floor reference so long as no raise occurs. The asymmetry that justified a Spec. Buy in July has inverted. At initiation we saw roughly -29% to +229% around a +112% base. Today we see -50% to +106% around a +25% base. A 25% base-case return does not compensate for a 50% downside case whose trigger — a financing before the October 31 facility deadline — is on a known calendar. ## Risk Update - Liquidity (HIGH, materially escalated): This has replaced customer concentration as the binding risk. Cash of C$374,671 at June 30 against an H1 operating burn of C$589,921 and investing outflow of C$650,605. The July sale-leaseback of the MALDI-TOF returns roughly C$300K to working capital and the 20% headcount cut should reduce H2 cash costs, but the runway on unchanged Q2 economics is measured in a small number of quarters, not years. - Facility Purchase Commitment (HIGH, new): The Company has signed a purchase agreement and paid a deposit on a permanent laboratory facility, with conditions — including financing approval — to be removed by October 31, 2026. Management is "engaged with financial institutions regarding financing." Two outcomes are unattractive: securing a mortgage adds fixed debt service to a business with negative Adj. EBITDAS, or walking away risks the deposit and leaves the multi-site occupancy problem unresolved. This is the most important dated event in the coverage. - Dilution (HIGH, new): Share count has not moved — 54,438,235 since December 2025 — and management states an objective of "minimizing shareholder dilution." But with C$375K of cash, a facility to finance, and no operating cash generation, an equity raise near current levels is a live possibility. At C$0.08, a C$1M raise would be roughly 23% dilution. - Revenue Base Reset (HIGH, was Customer Concentration): The risk has changed character. The concentrated client is gone and confirmed gone; the question is no longer "will they come back" but "what does the business earn without them." Two quarters of C$650–680K suggest an annual base near C$2.7M unless BD conversion materially accelerates. - Gross Margin / Utilization (HIGH, escalated from MEDIUM): An 8.6% gross margin on a fixed lab cost base is the clearest expression of the problem. Cost of sales rose 35% year over year on 31% lower revenue. The 20% headcount reduction should help in H2, but margin recovery to anything resembling the FY2025 52.9% requires volume the Company does not currently have. - Keystone Underperformance (MEDIUM, new): Reversal of the contingent consideration because milestones are "unlikely to be achieved" is a quiet admission that the November 2024 acquisition — which supplied most of the FY2025 revenue growth — is not performing to the terms underwritten at deal close. - Liquidity / Small-Cap Risk (HIGH, unchanged): Roughly C$4.36M market cap, no analyst coverage, and trading so thin that the last print before this report was 4,000 shares. The 52-week range is C$0.065 to C$0.29. Entry and exit are genuinely constrained. ## Conclusion We were wrong about the shape of this, and the honest thing is to say which part. The July thesis had two loads bearing on it: that the FY2025 revenue base was real and recoverable, and that the balance sheet bought management enough time to recover it. Q2 took out both. Management has now told us in plain language that the lost program is not coming back and that the underlying business is running at 2024 levels — which reframes FY2025 as a peak rather than a platform. And the cash that was supposed to fund the recovery was spent, substantially on capital equipment, at a rate that turned a C$1.29M net cash position into C$78K in six months. The perverse result is that the stock is 6% cheaper per share than at our initiation while its enterprise value is 29% higher — C$4.28M against C$3.31M — and the multiple paid on the relevant trailing revenue has gone from 0.73x to 1.15x. That is the cleanest statement of why the rating has to change: the dislocation we bought did not close through a price recovery, it closed through balance-sheet erosion. What remains is a real business — GMP-accredited, ISO-certified, two decades of biofilm expertise, C$2.59M of equity, positive net cash, no debt of consequence, and a management team that has now done the hard and unglamorous work of cutting 20% of headcount and admitting the customer is gone. That business is worth something more than C$4.36M. It is not obviously worth twice that in the next twelve months. What would move us back to Spec. Buy: two consecutive quarters of sequential revenue growth with gross margin back above 30%; the October 31 facility decision resolved without a dilutive equity raise; or visible conversion from the enlarged business development function into named multi-client revenue. What would move us to Avoid: a financing below C$0.06, or a third consecutive quarter near the C$650K revenue mark with margin still in the single digits. At C$0.08 per share and a C$4.36M market cap, we downgrade Innovotech to Hold with a C$0.10 price target. Holders should not be adding here; the next twelve weeks contain a financing decision that will determine whether the bear case or the base case is the right frame. --- # East Side Games Group Inc. (TSX: EAGR) — Equity Research - URL: https://microcapresearch.ca/reports/eagr-east-side-games-group-inc-2026-q2update - PDF: https://microcapresearch.ca/reports/eagr-east-side-games-group-inc-2026-q2update.pdf - Report ID: EAGR-2026-08-Q2update - Published: 2026-08-14 - Sector: Technology / Mobile Gaming - Rating: Avoid - Price target: C$0.06 - Price at publication: C$0.08 - Implied upside: -25% - Market cap: C$8.3M (basic) - Status: CURRENT **Bottom line:** Microcap Research rates East Side Games Group Inc. (TSX: EAGR) Avoid with a 12-month price target of C$0.06, about 25% below the C$0.08 share price at publication on Aug 14, 2026. Market capitalisation at publication: C$8.3M (basic). **Thesis:** Downgrade to Avoid. Management cut FY2026 guidance to C$40–44M revenue and C$4.0–4.7M Adj. EBITDA just ten weeks after reaffirming C$50–56M at the close of an insider private placement. Net debt rose to C$7.3M despite the C$2.96M raise, going-concern language is now explicit, and RBC has moved the account to Special Loans. Three of five thesis pillars are broken, and at 4.3x reduced guidance on adjusted EV the shares price in a refinancing that has not closed. ## Key statistics - Market Cap: C$8.3M - Adjusted EV: C$18.8M - EV / 2026E Adj. EBITDA: 4.3x - Revenue (Q2 2026): C$10.32M - Adj. EBITDA (TTM): C$0.44M - Gross Margin (Q2 2026): 59.1% ## Update Summary This update follows East Side Games Group's Q2 2026 earnings release on August 13, 2026. We downgrade our rating from Speculative Buy to Avoid and lower our 12-month price target to C$0.06 from C$0.24, representing approximately -25% versus the current price of C$0.08 (the closing price on 2026-08-13, the date of the earnings release, per Yahoo Finance). Management cut FY2026 revenue guidance to C$40–44M from C$50–56M and Adj. EBITDA guidance to C$4.0–4.7M from C$7.5–10.0M — ten weeks after reaffirming the original outlook at the closing of an insider-participating private placement. The interim financial statements now carry explicit going-concern language, and the Company's primary lender has transferred its credit facilities to Special Loans. Our initiation on EAGR was published May 9, 2026 (target C$0.30), revised to C$0.24 on May 20, 2026 following Q1. The original thesis held that a recapitalized free-to-play publisher with concrete management guidance was trading at roughly 2.0x guided 2026E Adj. EBITDA versus 4.7x for Western mobile peers. That thesis rested on the guidance being achievable and the May financing having cleared the solvency overhang. Q2 disproves both premises. ## What Changed - Guidance cut, twice over: FY2026 revenue guidance reduced to C$40–44M from C$50–56M (-21% at the midpoint) and Adj. EBITDA to C$4.0–4.7M from C$7.5–10.0M (-50% at the midpoint). The original outlook was explicitly reaffirmed on May 27, 2026 in the private placement closing release — at a point when roughly two months of the quarter's actuals were in hand and the quarter was tracking to C$10.3M. - Implied 2H is worse than reported 1H: Against 1H actuals of C$22.77M revenue and C$3.10M Adj. EBITDA, the new full-year guide implies 2H revenue of C$17.2–21.2M (C$8.6–10.6M per quarter, flat to down versus Q2) and 2H Adj. EBITDA of C$0.90–1.60M — a 2H margin of 5.2–7.5% versus 13.6% in 1H. The headline "10–12% margin" is a full-year blend that conceals sequential deterioration. - Lender moved the account to Special Loans: Disclosed only in Notes 1 and 19 — not in the MD&A and not in the press release. The Company has arranged to transition its operating line to a new financial institution, subject to formal approval from the incumbent bank. Both DSCR (minimum 1.25:1) and FDTER (maximum 2.50:1) were breached at June 30, and the full C$3.0M of drawn bank debt is classified as a current liability. - Explicit going-concern language: The interim statements now state a material uncertainty that may cast significant doubt on the Company's ability to continue as a going concern. This is an escalation from prior quarters. - Net debt rose despite the equity raise: Net debt of C$7.26M at June 30 versus C$6.6M at March 31 and C$5.0M at December 31, 2025 — up C$2.3M year-to-date notwithstanding C$2.96M of gross proceeds. The mix shifted from bank debt (C$5.26M to C$3.00M) to related-party debt (nil to C$5.58M). - Truly Social Games settled: C$3.0M cash (C$1.0M paid; C$2.0M in four semi-annual instalments of C$500K) plus 3,000,000 warrants at C$0.14 expiring November 2028. A one-time charge of C$3,130,800 was recognised. The contingent liability is resolved; C$2.0M of cash obligation replaces it. - Audience metrics deteriorated sequentially: DAU of 118,872 fell 41.3% year-over-year and 18.3% quarter-over-quarter; MAU of 401,902 fell 52.1% and 22.4% respectively. ARPDAU held flat sequentially at C$0.95. ## Thesis Check Reviewing each of the five pillars from our May 9 initiation: - Pillar 1 — The 2026 Guidance Is Concrete and Implies a >9x EBITDA Reset (BROKEN): The guidance was neither concrete nor durable. Cut by 21% on revenue and 50% on Adj. EBITDA within ten weeks of being reaffirmed. Guidance credibility was the load-bearing element of the initiation thesis and it has failed. - Pillar 2 — The May 2026 Financing De-Risks the Solvency Overhang (BROKEN): The raise did not de-risk solvency. Net debt is higher post-raise, going-concern language is now explicit rather than technical, and the account has moved to a workout group. Only C$325K of headroom remains on the C$5.0M related-party facility, which with C$1.33M of cash is the entire liquidity runway absent the unconfirmed refinancing. - Pillar 3 — Insider Conviction Is Substantial (WEAKENED — and materially recharacterised): Correction to our May 20 update: we attributed the director loan facility to Director Derek Lew. The Q2 related-party note identifies the counterparty as Bailey Ransen Family Trust , with C$5,866,194 included in the director loan facility and other payables. The lender is the family trust of Executive Chairman and CEO Jason Bailey, already the >50% controlling shareholder. Insider capital is real, but it is subordinated secured debt at 8% maturing March 5, 2028 — not equity conviction. The controlling shareholder now holds the fulcrum instrument in any restructuring, which is a governance concern rather than a positive signal. - Pillar 4 — The Core Portfolio Is a Real Cash-Generating Asset (WEAKENED): Partially validated: the portfolio produced C$10.3M of revenue in Q2 on only C$1.21M of sales and marketing spend, down 82% year-over-year. But 1H Adj. EBITDA of C$3.10M was almost entirely consumed by C$2.76M of capitalised development and prepaid development costs, leaving C$0.34M before interest, settlement instalments and any debt reduction. Intangibles declined from C$7.70M to C$6.50M as capitalised spend ran below amortisation. The asset generates cash; it does not generate free cash. - Pillar 5 — Valuation Is Distressed-Pricing for a Recapitalized Business (BROKEN): The business is not recapitalized. On adjusted enterprise value including the settlement obligation and minimum guarantees, EAGR trades at approximately 4.3x the midpoint of the reduced guidance — versus the 2.0x on prior guidance cited at initiation, and against a 4.7x peer benchmark that assumes no workout status. The discount has closed for the wrong reasons. ## Updated Financials | Metric | Q2 2025 | Q1 2026 | Q2 2026 | YoY Change | | Revenue (C$M) | 19.22 | 12.45 | 10.32 | -46.3% | | Gross Profit (C$M) | 11.93 | 7.46 | 6.09 | -48.9% | | Gross Margin | 62.1% | 59.9% | 59.1% | -300 bps | | Adj. EBITDA (C$M) | 1.54 | 1.74 | 1.37 | -11.2% | | Adj. EBITDA Margin | 8.0% | 14.0% | 13.2% | +520 bps | | EBITDA (C$M) | 1.27 | 0.60 | (2.76) | n/m | | Net Loss (C$M) | (1.36) | (3.62) | (4.52) | n/m | | Sales & Marketing (C$M) | 6.68 | 2.33 | 1.21 | -81.9% | | DAU | 202,530 | 145,581 | 118,872 | -41.3% | | ARPDAU (C$) | 1.04 | 0.95 | 0.95 | -8.5% | | Net Debt (C$M) | n/a (net cash) | 6.60 | 7.26 | n/m | Q2 2025 Adj. EBITDA restated by the Company to C$1.537M from C$1.554M as originally reported. Adj. EBITDA add-backs for "transaction, litigation and restructuring charges" totalled C$4.26M in Q2 2026 and C$7.22M over the trailing four quarters, against trailing-twelve-month Adj. EBITDA of C$0.44M. ## Updated Valuation Our valuation framework is unchanged in method — EV/Adj. EBITDA with a scenario range — but two inputs have moved materially. First, the earnings base is now management's reduced guidance of C$4.0–4.7M rather than the C$7.0M base case we carried after Q1. Second, we now capitalise the full obligation stack rather than net debt alone: the C$2.0M Truly Social Games settlement liability and C$1.24M of minimum guarantee commitments are contractual cash obligations that sit ahead of equity and were not captured in our prior work. | Item | Amount (C$M) | | Market capitalisation (103,843,096 shares at C$0.08) | 8.31 | | Bank indebtedness (classified current) | 3.00 | | Director loan facility (Bailey Ransen Family Trust) | 5.58 | | Less: cash | (1.33) | | Settlement obligation (current + non-current) | 2.00 | | Minimum guarantees (current + non-current) | 1.24 | | Adjusted enterprise value | 18.80 | At C$18.80M adjusted EV against the C$4.35M midpoint of reduced guidance, EAGR trades at approximately 4.3x forward Adj. EBITDA — above the 3.5x we consider appropriate for a covenant-breached issuer in bank special loans, and close to the 4.7x Western mobile peer benchmark that assumes an ordinary-course balance sheet. All 31,146,816 outstanding warrants strike at C$0.14 and are out of the money at C$0.08, so basic shares are the correct count today; the overhang becomes 30% dilution if the shares recover past C$0.14. | Scenario | Basis | Price / Share | vs. Current | | Bear Case | Refinancing fails; 3.5x on C$3.2M (guidance -25%) | C$0.01 | -88% | | Base Case | 3.5x on C$4.35M guidance midpoint | C$0.045 | -44% | | Bull Case | Refinancing closes; 4.7x peer multiple on C$4.7M | C$0.112 | +40% | Probability-weighted at 25% bear / 45% base / 30% bull, the scenario range implies approximately C$0.056. Our C$0.06 target reflects that weighting rounded. We weight the bull case below one-in-three because it requires both the refinancing to close and the reduced guidance to be met, and the reduced guidance is itself two weeks old. ## Risk Update - Refinancing execution risk (HIGH — new): The entire bull case rests on a single unexecuted event. The new facility is subject to formal approval from the incumbent bank, with no counterparty named and no binding commitment disclosed. Failure converts this position to the bear case with little warning. - Borrowing base contraction (HIGH — new): The bank operating line carries a C$7.0M limit but is subject to a borrowing base of 85% of eligible receivables. Trade receivables fell from C$8.57M to C$3.99M, putting the borrowing base near C$3.39M against C$3.00M drawn. Available credit now contracts automatically as revenue declines — a self-reinforcing mechanism, and the C$4.57M receivables release that funded the half is not repeatable. - Related-party creditor concentration (HIGH — escalated): The controlling shareholder's family trust is owed C$5.87M and holds only C$325K of undrawn capacity. Separately, C$997,693 was paid to Night Garden, a related party by common directorship, during 1H 2026 while the Company was in covenant breach. - Adj. EBITDA quality (HIGH — escalated): C$7.22M of "non-recurring" charges across four consecutive quarters against C$0.44M of trailing Adj. EBITDA. When add-backs exceed the adjusted result by a factor of sixteen over a full year, the adjustment is describing the cost of operating the business. - Disclosure quality (MEDIUM — new): The Special Loans transfer appears only in the notes, absent from both MD&A and press release. The going-concern note cites a six-month net loss of C$4,507,671 and cash used of C$2,520,036, neither of which reconciles to the face statements (C$8,141,529 and C$2,532,636 respectively). The December 31, 2025 comparative was restated to move C$908,927 from trade payables into the director loan facility without narrative disclosure, and that non-cash reclassification is grossed up through the cash flow statement as both a financing inflow and an operating outflow. The statements are unaudited and unreviewed. - EDC facility is ring-fenced (MEDIUM — clarified): The US$4.0M Export Development Canada facility is in final approval stages, but proceeds are restricted exclusively to new game development and must be advanced within six months of approval. It cannot fund debt repayment, the settlement instalments, or working capital. - User acquisition restart (MEDIUM — new): Management intends to materially expand UA spend from mid-August. Underlying cash operating expense of approximately C$4.86M per quarter against C$6.09M of gross profit implies an Adj. EBITDA breakeven near C$8.2M of quarterly revenue; UA sits inside that cost base, so expanding it raises the breakeven directly against a revenue line still declining 18% sequentially. - Liquidity and small-cap risk (HIGH — unchanged): Average daily volume is minimal and the shares trade near an all-time low of C$0.06 set June 9, 2026. Position exit at scale is impractical. ## Conclusion The thesis we published in May was that concrete guidance plus a completed financing had converted EAGR from a solvency story into a valuation story. Q2 reverses that. Guidance proved unreliable within ten weeks of reaffirmation, the financing did not reduce net debt, the going-concern qualification became explicit, and the primary lender moved the account to a workout group. Three of five pillars are broken and the remaining two are weakened. We were wrong to underwrite management's outlook at face value, and we compounded it by mis-identifying the related-party lender in our Q1 update. What remains is genuinely a binary. If the refinancing closes on the terms described, EAGR is a small, cash-generative game portfolio with a repaired capital structure trading at a defensible multiple, and the bull case is live. If it does not, the C$3.0M of current bank debt is callable against C$1.33M of cash and C$325K of remaining insider capacity, and the equity is close to worthless. That distribution is not adequately compensated at C$0.08. Our probability-weighted fair value of approximately C$0.056 sits roughly 30% below the market price, and the base case — management hitting its own freshly reduced guidance, valued at a multiple appropriate to a workout borrower — implies C$0.045. The shares already price in a successful refinancing that has not been signed. An investor buying here is not being paid to underwrite that risk; they are paying for the privilege of taking it. What to watch: formal confirmation of the new credit facility and its covenant package; Q3 DAU, which must stabilise near 118,000 for the reduced guidance to hold; the incremental Adj. EBITDA impact of the mid-August UA restart; and whether the Q3 filing carries the same disclosure inconsistencies as this one. At C$0.08 per share and a C$8.3M market capitalisation, we downgrade EAGR to Avoid from Speculative Buy and lower our 12-month price target to C$0.06 from C$0.24. We would revisit the rating on formal confirmation of the new credit facility, which would remove the binary and return this to a valuation discussion. --- # Innovotech Inc. (TSXV: IOT) — Equity Research - URL: https://microcapresearch.ca/reports/iot-innovotech-inc-2026 - PDF: https://microcapresearch.ca/reports/iot-innovotech-inc-2026.pdf - Report ID: IOT-2026-07 - Published: 2026-07-02 - Sector: Life Sciences Services / Laboratory Testing - Rating: Spec. Buy - Price target: C$0.18 - Price at publication: C$0.085 - Implied upside: 112% - Market cap: C$4.63M - Status: SUPERSEDED > **This Jul 2, 2026 report is no longer current. Microcap Research has since changed its rating on Innovotech Inc. (IOT) from Spec. Buy to Hold, with a C$0.10 price target, in the Aug 19, 2026 update.** Current report: https://microcapresearch.ca/reports/iot-innovotech-inc-2026-q2update **Bottom line:** Microcap Research rates Innovotech Inc. (TSXV: IOT) Spec. Buy with a 12-month price target of C$0.18, about 112% above the C$0.085 share price at publication on Jul 2, 2026. Market capitalisation at publication: C$4.63M. **Thesis:** A textbook microcap dislocation: a GMP-accredited lab-services business that doubled revenue to C$4.53M and earned a profit in 2025, now trading at ~0.73x EV/Revenue after a single client program ended and cratered Q1 2026 revenue 44%. With C$1.32M cash, a 3.28x current ratio, and GLP certification underway, the market is pricing a real stumble as if it were terminal. ## Key statistics - Market Cap: C$4.63M - EV/Revenue (FY2025): ~0.73x - Revenue (FY2025): C$4.53M (+107%) - Gross Margin (FY2025): 52.9% - Cash (Q1 2026): C$1.32M - Q1 2026 Revenue: C$0.65M (-44%) ## Executive Summary Innovotech Inc. (TSXV: IOT; OTCQB: IOTCF) is an Edmonton-based life sciences services company built around applied microbiology, analytical chemistry, and regulated laboratory testing. Its two historical operating pillars — Innovotech Labs (antimicrobial and biofilm contract research, home of the proprietary MBEC Assay® kit and the InnovoSIL™ silver platform) and Keystone Labs (GMP-accredited pharmaceutical and analytical testing, acquired in late 2024) — were amalgamated into a single operating entity on January 1, 2026. In fiscal 2025 the combined business more than doubled revenue to C$4.53M (+107% YoY), delivered a 52.9% gross margin, and posted positive full-year net income of C$0.09M. The setup is a textbook microcap dislocation. In Q1 2026 revenue collapsed 44% YoY to C$0.65M after a single large customer wound down a project that management had staffed and resourced for through 2026. The quarter swung to a C$0.40M net loss, and the stock has fallen roughly 60% over the past year and ~48% in the last month to C$0.085. Yet the company still carries C$1.32M of cash, C$1.79M of working capital, a 3.28x current ratio, and essentially no debt — and the underlying FY2025 revenue base is more than double what it was two years ago. We initiate coverage with a Spec. Buy rating and a 12-month price target of C$0.18, representing approximately 112% upside from current levels of C$0.085 (as of 2026-07-02, per user-provided quote; last close C$0.11 on June 4, 2026 per Yahoo Finance). At an enterprise value of roughly C$3.3M against C$4.53M of FY2025 revenue, IOT trades at ~0.73x EV/Revenue — a distressed multiple for a profitable-in-2025, GMP-accredited lab-services platform. The market is pricing the Q1 client loss as terminal; we think it is a real but survivable stumble against a doubled revenue base and a cash-cushioned balance sheet. ## Company Overview Innovotech operates ISO-certified and GMP-accredited laboratories serving medical-device, pharmaceutical, and industrial clients across Canada, the United States, and international markets. Following the January 2026 amalgamation, the business now reports as a single operating segment, but its revenue still spans several distinct service lines: - Antimicrobial & biofilm contract research: The legacy Innovotech Labs franchise — biofilm science, antimicrobial and medical-device testing, and the globally used MBEC Assay® platform. This is the higher-margin, IP-anchored core, but also the most project-concentrated. Q1 2026 antimicrobial testing revenue was C$0.30M, down from C$0.77M a year earlier. - GMP, analytical chemistry & stability testing: The Keystone Labs franchise — regulated pharmaceutical testing, HPLC method development, environmental monitoring, and stability studies. This line proved far more resilient, at C$0.29M in Q1 2026 versus C$0.33M a year prior, and is the diversification engine of the thesis. - Products (MBEC Assay® kits): Manufactured consumables sold worldwide to academic, industrial, and government labs (C$0.05M in Q1 2026). Small but sticky, and a marketing funnel into contract research. - Proprietary IP (InnovoSIL™ silver): A family of silver-periodate antimicrobial compounds in active R&D, supported by non-dilutive grant funding (AICE-Validates, NRC IRAP), targeting wound dressings, coatings, and 3D-printed resins. Pre-revenue optionality, not modeled in our valuation. In 2025, Keystone's full-year inclusion drove the segment split to C$3.16M from Innovotech Labs (ILC) and C$1.38M from Keystone (KLI), the latter up 559% on a partial-year 2024 base. Geographically, the U.S. remained the largest market at C$2.94M, with Canada growing to C$1.36M on Keystone's domestic client base. ## Investment Thesis — Five Pillars ### 1. The FY2025 Scale-Up Was Large, Real, and Profitable This is not a story stock with no revenue. In fiscal 2025 Innovotech generated C$4,534,852 of revenue, up 107% from C$2,194,471 in 2024 and nearly 4x the C$1,182,632 posted in 2023. Gross profit reached C$2,397,039 at a 52.9% margin, and the company delivered positive net income of C$0.09M for the full year despite deliberately prioritizing growth investment over near-term profit. The scale-up was driven by both the Keystone acquisition and genuine organic momentum: in Q2 and Q3 2025, revenue rose C$0.59M and C$0.83M respectively versus the prior-year quarters, of which organic growth contributed C$0.20M and C$0.50M. A company that can quadruple revenue over two years and turn a profit while doing so has a demonstrably real underlying business — which is precisely what a ~C$4.6M market cap disputes. ### 2. The Valuation Discounts a Permanent Impairment That the Balance Sheet Contradicts At C$0.085 per share and 54.44M shares outstanding, IOT's market cap is ~C$4.63M. Net of C$1.32M cash and negligible debt, enterprise value is ~C$3.31M — just 0.73x FY2025 revenue and roughly 1.4x FY2025 gross profit. Regulated CRO and analytical-testing peers typically command well north of 1x sales even in weak tapes; a franchise with GMP accreditation, proprietary IP, and 50%+ historical gross margins changing hands below 1x revenue implies the market expects the revenue base to stay near Q1 2026's annualized run-rate permanently. The balance sheet argues otherwise: C$1.79M working capital, a 3.28x current ratio, and C$4.30M of total assets against C$1.05M of total liabilities give the company room to fund a diversification-led recovery without forced dilution at these levels. ### 3. Q1 2026 Exposed the Concentration Risk — But Also the Catalyst for Fixing It The Q1 2026 revenue cliff (C$0.65M, -44% YoY) was, in management's own words, "a worst-case realization of customer concentration risk": a single major customer's anticipated program did not continue, and because the company had held staffing and capacity ready for that work, the miss flowed straight through to a C$0.40M net loss and a C$0.35M Adjusted EBITDAS loss on underutilized capacity. The important nuance is that the GMP/analytical/stability line held roughly flat (C$0.29M vs C$0.33M) while the antimicrobial line took the hit — validating diversification as the fix. Management is responding directly: a new Chief Commercial Officer, an expanded sales organization, a redesigned corporate website, and a redirected cost base toward recurring, multi-client revenue. The event that broke the quarter is the same event forcing the structural change the business needed. ### 4. GLP Certification Is a Structural Market Expander, Not an Incremental Upgrade Innovotech is pursuing Good Laboratory Practice (GLP) certification, transitioning accreditation oversight from CALA to the Standards Council of Canada. Management frames GLP not as a marginal enhancement but as a structural enabler that opens participation in higher-value, longer-duration regulated development programs — the kind of multi-year, stickier work that directly counters the project-based volatility that hurt Q1. GLP-aligned services are a frequent client request the company currently cannot fully serve. If achieved, GLP materially expands the addressable market and shifts the revenue mix toward exactly the recurring, regulated work the thesis depends on. The associated compliance costs are already being absorbed in the current P&L, so the earnings drag is front-loaded and the option is live. ### 5. Optionality: U.S. Capital-Markets Access, IP, and Owned Infrastructure Several call options sit on top of the core recovery. The company completed an OTCQB (IOTCF) listing in early 2026 and is expanding U.S. investor outreach, widening the potential shareholder base for a name with almost no current institutional following. The InnovoSIL™ silver platform — advancing through grant-funded trials in wound dressings, polymer coatings, and 3D-printed resins — is pre-revenue but represents genuine partnering/licensing upside not in our numbers. And management is evaluating the acquisition of a permanent, purpose-built laboratory facility to stabilize occupancy costs and support certification and expansion, converting escalating Edmonton lease exposure into controllable, financed fixed infrastructure. None of these are required for the thesis to work, but each is a way to win. ## Financial Summary | Metric | FY2024 | FY2025 | YoY Change | | Revenue (C$M) | 2.19 | 4.53 | +107% | | Gross Profit (C$M) | 1.11 | 2.40 | +116% | | Gross Margin | 50.6% | 52.9% | +2.3 pts | | Net Income (C$M) | 0.21 | 0.09 | -59% | | Cash (period-end, C$M) | 1.62 | 1.32* | -19% | *Cash of C$1.32M is as of March 31, 2026 (Q1 2026 period-end); FY2025 year-end cash was C$1.62M. FY2025 net income of C$0.09M reflects deliberate reinvestment (staffing, capacity, sales build-out); management noted growth was prioritized over short-term profit. Q1 2026 revenue was C$0.65M (-44% YoY) with a net loss of C$0.40M. ## Valuation We anchor valuation on EV/Revenue given the project-based volatility in near-term earnings. At an EV of ~C$3.31M, IOT trades at ~0.73x FY2025 revenue — a level that implies structural impairment rather than a single lost contract. Our base case applies a still-conservative ~1.9x EV/Revenue to the doubled FY2025 base, a multiple that remains a discount to regulated CRO/analytical-testing comparables and does not credit any GLP-driven mix shift or InnovoSIL™ optionality. The bear case assumes the Q1 run-rate becomes the new normal and the market holds the business near current distressed multiples; the bull case assumes diversification and GLP restore growth and re-rate the multiple toward peer levels. | Scenario | Basis | Price / Share | vs. Current | | Bear Case | ~0.9x EV/Rev on impaired run-rate | C$0.06 | -29% | | Base Case | ~1.9x EV/Rev on FY2025 revenue | C$0.18 | +112% | | Bull Case | ~3.0x EV/Rev on recovering, GLP-enabled base | C$0.28 | +229% | Share count of 54,438,235 and cash of C$1.32M used throughout. Bull case is set near the 52-week high of C$0.34 and assumes revenue recovery plus multiple re-rating; it is not our base assumption. ## Key Risks - Customer Concentration (HIGH): Q1 2026 proved a single client can erase ~44% of revenue in a quarter. Until the client base is demonstrably broadened, quarterly results will remain volatile and a second concentrated loss would be severe. - Cash Burn & Capex (HIGH): The company swung to a C$0.40M quarterly loss and negative Adjusted EBITDAS while carrying C$1.32M cash and simultaneously evaluating a permanent-facility purchase and GLP certification. A prolonged revenue trough combined with heavy capex could pressure liquidity and force dilution at depressed prices. - Execution on Diversification & GLP (MEDIUM): The entire recovery thesis rests on management successfully diversifying revenue and achieving GLP certification on a reasonable timeline. Both are within management's control but neither is guaranteed, and GLP timing is inherently uncertain. - Liquidity / Small-Cap Risk (HIGH): Average daily volume is roughly 39,000 shares with zero analyst coverage. The stock is thinly traded and can gap on modest order flow; entry and exit are difficult, and the OTCQB listing has not yet produced meaningful float depth. - Integration & Management Transition (MEDIUM): The 2026 amalgamation, a facility relocation, executive departures in 2025, and a June 2026 CFO change all introduce operational and continuity risk during a fragile period. - Margin Recovery (MEDIUM): Gross margin fell to 31.2% in Q1 2026 on underutilized capacity from the 52.9% FY2025 level. Margins only normalize if utilization recovers; a slow rebuild keeps profitability negative. ## Conclusion Innovotech is a real, GMP-accredited laboratory-services business that doubled revenue and earned a profit in 2025, now trading as if the franchise is permanently impaired because a single client program ended in Q1 2026. The stumble is genuine — concentration risk materialized in the worst way, the quarter swung to a loss, and the company is burning cash while investing through the trough. But the balance sheet (C$1.32M cash, C$1.79M working capital, 3.28x current ratio, minimal debt) buys management the runway to execute the exact fix the situation demands: diversify the client base, lean on the resilient GMP/analytical line, and pursue GLP certification to move into stickier, higher-value regulated work. The risk/reward is asymmetric at these levels. The bear case still assumes the business survives near a distressed multiple; the base and bull cases require only that a doubled, profitable-in-2025 revenue base is not permanently gone. We view the primary overhang — will the revenue recover — as a question the market has already answered pessimistically, leaving room for upside if execution merely stabilizes results. At C$0.085 per share and a ~C$4.63M market cap, IOT trades at roughly 0.73x FY2025 revenue with cash equal to nearly 30% of its market value. We rate IOT Spec. Buy with a C$0.18 price target. --- # Avricore Health Inc. (TSXV: AVCR) — Equity Research - URL: https://microcapresearch.ca/reports/avcr-avricore-health-inc-2026 - PDF: https://microcapresearch.ca/reports/avcr-avricore-health-inc-2026.pdf - Report ID: AVCR-2026-06 - Published: 2026-06-11 - Sector: Healthcare / Point-of-Care Diagnostics (Pharmacy Technology) - Rating: Spec. Buy - Price target: C$0.11 - Price at publication: C$0.05 - Implied upside: 120% - Market cap: C$5.1M - Status: CURRENT **Bottom line:** Microcap Research rates Avricore Health Inc. (TSXV: AVCR) Spec. Buy with a 12-month price target of C$0.11, about 120% above the C$0.05 share price at publication on Jun 11, 2026. Market capitalisation at publication: C$5.1M. **Thesis:** A deliberate, high-stakes pivot: Avricore walked away from the Shoppers Drug Mart contract (~97% of revenue) to bet entirely on the UK NHS pharmacy market, collapsing revenue ~90% and triggering going-concern doubt. At a ~C$5M market cap with ~700 analyzers staged, blue-chip NHS partners, and a September 2026 national independent-prescriber rollout, the stock is a cheap option on UK execution — with first subscription revenue expected H2 2026. ## Key statistics - Market Cap: C$5.1M - Cash (Q1 2026): C$0.20M - Revenue (FY2025): C$0.53M (-89%) - Net Loss (FY2025): C$(1.86)M - UK HealthTab Systems: 59 (Mar 2026) - Insider Ownership: ~8.0% ## Executive Summary Avricore Health Inc. (TSXV: AVCR; OTCQB: AVCRF) is a Vancouver-based pharmacy-technology company whose wholly owned HealthTab™ platform turns community pharmacies into point-of-care diagnostic centres — pairing Abbott Afinion™ 2 and ID Now™ analyzers with a cloud platform that captures results, runs quality control, and integrates into electronic health records. The platform screens for chronic disease (HbA1c, lipids, eGFR; up to ~27 biomarkers) and monetizes through system/subscription fees, consumables, and prospective program and data revenue. The setup is a deliberate, high-stakes pivot. The Company allowed its Shoppers Drug Mart contract — which represented roughly 97% of revenue from a single customer — to expire on March 31, 2025, and redirected the entire business toward the UK NHS pharmacy market. Reported revenue consequently collapsed 89% to C$533,884 in FY2025 (from C$4.79M in FY2024) and a further 90% year-over-year in Q1 2026 to C$44,315. The auditors flag material going-concern uncertainty, and working capital fell to just C$11,574 at March 31, 2026 against C$200,301 of cash. This is, unambiguously, a story-stage turnaround with a near-empty balance sheet. What makes it interesting at a ~C$5M market capitalization is the asymmetry. The UK opportunity Avricore is building into is larger, more recurring, and backed by unusually specific government funding and dated regulatory deadlines. The Company has staged ~700 analyzers into the UK (requiring no new device capex for 12–18 months), grown its UK installed base from 38 systems (December 2025) to 59 (March 2026), and assembled blue-chip NHS partners. A May 2026 C$1.25M private placement at C$0.05 (half-warrant at C$0.10) extends runway into the key catalyst window. We initiate coverage with a Speculative Buy rating and a 12-month price target of C$0.11, representing approximately 120% upside from current levels of C$0.05 (as of 2026-06-11, per StockAnalysis.com). At a ~C$5M market cap, AVCR is priced as a cheap option on UK NHS execution, with dated near-term catalysts (national independent-prescriber rollout from September 2026; first UK subscription revenue expected H2 2026) — explicitly gated by going-concern risk and the complete absence of proven UK revenue to date. This is a binary, speculative bet to be sized accordingly, not a core holding. ## Company Overview Avricore Health (formerly Vanc Pharmaceuticals; renamed in 2018) is incorporated in British Columbia and trades on the TSX Venture Exchange under AVCR and on the OTCQB as AVCRF. Its sole operating asset is HealthTab™, held through UK subsidiary HealthTab Ltd. The platform is a complete, turnkey POCT solution combining instruments, cloud software, standardized workflows, training, and a quality-management program run with CEQAL Inc. (a CDC Cholesterol Reference Method Laboratory Network member). As at the report date there were 101,289,664 common shares outstanding, 13,098,000 stock options, and no warrants; the Company carries no debt and had an accumulated deficit of C$34.3M at year-end 2025. - UK NHS (the focus, currently pre-revenue): 59 HealthTab systems deployed at March 31, 2026 (46 in North East London, 6 in North Central London, 7 elsewhere), operating within grant-funded NHS pilots alongside Barts Health NHS Trust, UCLPartners, the British Heart Foundation, and HEART UK. - Canada (Rexall, residual): 22 HealthTab systems at March 31, 2026 (14 Ontario, 7 Alberta, 1 Saskatchewan), plus an Ascensia Diabetes Care glucose-monitoring integration. Provincial reimbursement for HbA1c/lipid testing remains limited. ## Investment Thesis — Five Pillars ### 1. The UK Regulatory Tailwind Is Real, Dated, and Specific This is the crux of the thesis. On May 29, 2026, the UK Department of Health and Social Care and NHS England agreed a £340M community-pharmacy funding deal for 2026–27 that rolls out NHS-funded Independent Prescribing nationally from autumn 2026. From September 2026, every newly qualified English pharmacist graduates as an independent prescriber. The deal builds on the Pharmacy First service, which delivered over 3.3 million consultations in the year to February 2026, up 43% year-over-year. Independent prescribing structurally requires point-of-care testing to support diagnosis and monitoring — exactly what HealthTab sells. The health-economic case is already quantified: the NHS Confederation pegged community-based cardiovascular screening ROI at £7.52 per £1 spent (and £9 for diabetes), describing community-pharmacy CVD detection as providing the quickest return, within one year. With nearly 12,000 UK pharmacies, more than half already conducting ~250,000 blood-pressure screenings per month, the infrastructure and policy direction are aligned with Avricore's product. Few microcaps have a tailwind this concrete or this well-timed. ### 2. Early NHS Traction With Blue-Chip Validation The UK installed base grew from 38 systems (December 1, 2025) to 59 (March 31, 2026). More than 3,500 patients have been screened across North East and North Central London with Barts Health NHS Trust; in an initial 556-patient lipid cohort, roughly one in five was flagged as elevated cardiovascular risk. A one-month HbA1c pilot completed 2,295 tests across 57 sites — a per-location rate approximately 10x what the Company ever achieved in Canada. Critically, HealthTab has moved beyond screening into secondary prevention via a British Heart Foundation grant-funded pilot delivering inclisiran cholesterol-lowering injections through community pharmacies (part of the ELoPE-CVD programme). The platform integrates with the NHS App via Patient Knows Best (4.8 million users) and into hospital clinical systems via Ortus-iHealth, positioning it as care-pathway infrastructure rather than a standalone screening tool. Independent evaluation by UCLPartners, attention from NHS England's Chief Pharmaceutical Officer, and BBC National News coverage are soft but real credibility signals for a company this small. ### 3. Asset-Light Redeployment Lowers the Capital Bar Management staged ~700 analyzers and supporting hardware from the wound-down Canadian fleet to its London office and states it needs no new device capex for the next 12–18 months. For a company with ~C$0.2M of cash, this is the most important operational fact in the thesis: the UK scale-up is largely a deployment-and-monetization exercise rather than a capital-intensive hardware build. It also means the impairment taken on idle Canadian equipment (C$493,544 in FY2025) is reversible into income as devices are redeployed. ### 4. Optionality Is Cheap at This Market Capitalization At C$0.05 and ~C$5M market cap, enterprise value is essentially the UK option net of ~C$0.2M cash. The published roadmap (“The Path Forward”) targets 100+ active UK sites in Q2 2026, monthly subscription revenue beginning in H2 2026, 500+ UK locations by mid-2027, and a stated return to profitability by Q3 2027 — against a long-term addressable market of 10,000+ pharmacies across 42 NHS integrated care boards. If even the mid-2027 target lands on a recurring-revenue model, revenue could exceed the prior ~C$4.8M Canadian peak, against which today's valuation looks small. ### 5. Aligned, Domain-Credentialed Leadership CEO Rodger Seccombe (appointed June 4, 2025) is the founder/CTO who co-developed the technology and personally holds 4,880,611 shares; insiders and directors own ~8.0% (8,065,229 shares) and are expected to participate in the current financing. The board carries genuine pharmacy weight: Alan Arnstein scaled Medicine Shoppe from 28 to 175 stores; Christine Hrudka is a practising pharmacist and owner; Dr. Robert Sindelar is Dean Emeritus of UBC's Faculty of Pharmaceutical Sciences. Cash compensation is modest for the sector (CEO consulting fees of C$216,000; CFO C$128,400 in FY2025). ## Financial Summary | Metric | FY2024 | FY2025 | YoY Change | | Revenue (C$M) | 4.79 | 0.53 | -89% | | Gross Profit (C$M) | 1.88 | 0.24 | -87% | | Gross Margin | 39.3% | 44.6% | +530 bps | | Net Loss (C$M) | (0.67) | (1.86) | n/m | | Cash (period-end, C$M) | 1.13 | 0.23 | -80% | Q1 2026 (three months ended March 31, 2026): revenue C$44,315 (-90% YoY); gross loss C$(8,580); comprehensive loss C$204,218 — the smallest quarterly loss in two years as management eliminated former-CEO management fees and cut consulting, professional, and travel costs. Cash was C$200,301 and working capital just C$11,574. No debt. Customer concentration persists: ~71% of trade receivables from a single customer. ## Valuation Conventional multiples are not meaningful here — revenue is at a deliberate trough and EV/Revenue on trailing figures is distorted. The appropriate frame is a scenario range on UK execution and re-rating over a 12-month horizon. Note that management's own May 2026 financing was struck at C$0.05 with warrants exercisable at C$0.10 over 24 months, anchoring C$0.10 as an insider-endorsed multi-year aspiration. Our C$0.11 base-case target sits just above that warrant strike and roughly at the stock's 52-week high (C$0.045–C$0.10 range). | Scenario | Basis | Price / Share | vs. Current | | Bear Case | Financing underwhelms, monetization slips, further dilution / going-concern impact | C$0.02–0.03 | -40% to -60% | | Base Case | 100+ UK sites by Q2'26, subscription revenue starts H2'26, Sept'26 prescriber catalyst drives re-rate toward warrant strike | C$0.11 | +120% | | Bull Case | Clear, accelerating UK monetization; credible path to a national network re-rates to ~C$18–22M cap | C$0.18–0.20 | +260% to +300% | The C$1.25M placement (if fully subscribed) adds ~25M shares (~25% dilution) plus up to ~12.5M warrants at C$0.10; scenario prices are on a pre-/early-dilution basis and would compress modestly on full warrant exercise. ## Key Risks - Going Concern / Liquidity (HIGH): At March 31, 2026 the Company had C$200,301 of cash and just C$11,574 of working capital, with auditors flagging material going-concern uncertainty. The C$1.25M financing, if fully subscribed, buys an estimated 12–18 months; anything short of full subscription puts the Company back in the market quickly, likely at dilutive prices. - No Proven UK Revenue (HIGH): Every UK system today operates within grant-funded NHS pilots. Monthly subscription revenue is “expected” to begin in H2 2026 and is entirely unproven — the single most important unvalidated assumption in the thesis. If the pilots do not convert to a commissioned, paid service, there is no business model behind the installed base. - Execution / Single-Market Concentration (MEDIUM): The Company has bet its future on the UK NHS, where procurement and commissioning cycles are slow and the independent-prescriber rollout could slip. Having already exited its Canadian anchor customer, there is no fallback revenue base. - Dilution / Warrant Overhang (MEDIUM): The May 2026 placement adds ~25M shares and up to ~12.5M warrants struck at C$0.10, plus broker warrants — capping near-term upside around the warrant strike and likely necessitating further raises to reach the mid-2027 targets. - Microcap Liquidity (MEDIUM): Average daily volume is roughly 30,000 shares with frequent zero-movement days. Building or exiting a position of any size is difficult without materially moving the price. - Customer Concentration (MEDIUM): Despite the SDM exit, ~71% of trade receivables remained tied to a single customer at March 31, 2026, leaving residual concentration risk in the legacy Canadian business. ## Conclusion Avricore is a binary, story-stage speculation: a company that intentionally surrendered ~97% of its revenue to chase a larger, recurring, government-funded opportunity, and now must prove it can monetize that opportunity before its cash runs out. The bear case is a genuine near-zero. The bull case is a multi-bagger if the UK NHS network scales on a subscription model as outlined. What tilts the risk/reward favourably at these levels is the convergence of cheap optionality and dated catalysts. The downside is small in absolute dollars; the upside is several multiples if UK monetization lands. The September 2026 national independent-prescriber rollout, the £340M community-pharmacy funding deal, and the first expected UK subscription revenue in H2 2026 are concrete, near-term tests of the thesis. Investors should watch three things in order: the financing closing in full, the installed base crossing 100+ UK sites, and the first dollar of recurring UK revenue actually printing. At C$0.05 per share and a ~C$5M market cap, AVCR is priced as a distressed option rather than a company sitting on a policy tailwind this specific. We rate AVCR Speculative Buy with a C$0.11 price target. A defensible alternative is Hold until the raise closes and the first UK subscription revenue is confirmed. --- # Novra Technologies Inc. (TSXV: NVI) — Equity Research - URL: https://microcapresearch.ca/reports/nvi-novra-technologies-inc-2026-q1update - PDF: https://microcapresearch.ca/reports/nvi-novra-technologies-inc-2026-q1update.pdf - Report ID: NVI-2026-06-Q1update - Published: 2026-06-02 - Sector: Communications Equipment / Satellite Infrastructure - Rating: Spec. Buy - Price target: C$0.30 - Price at publication: C$0.16 - Implied upside: +88% - Market cap: C$5.3M - Status: CURRENT **Bottom line:** Microcap Research rates Novra Technologies Inc. (TSXV: NVI) Spec. Buy with a 12-month price target of C$0.30, about 88% above the C$0.16 share price at publication on Jun 2, 2026. Market capitalisation at publication: C$5.3M. **Thesis:** Q1 FY2026 tested the thesis without breaking it: revenue fell 36% to C$0.89M on thin backlog and the quarter slipped to a C$74K loss, but gross margin hit 57.2%, cash tripled to C$4.1M, equity turned positive, and the Lilikoi AIoT path and Government & Defense division advanced. We trim our target to C$0.30 on a smaller trailing earnings base while maintaining Spec. Buy — but SNAPS is about to cross 20% and become a Control Entity at the June 26 vote. ## Key statistics - Market Cap: C$5.3M - EV/Adj. EBITDA (LTM): ~3.9x - EV/Revenue (LTM): 0.73x - Revenue (Q1 FY26): C$0.89M - Gross Margin (Q1): 57.2% - Cash (Mar 31): C$4.1M ## Update Summary This update follows Novra's Q1 FY2026 results (three months ended March 31, 2026), filed June 1, 2026. We maintain our Spec. Buy rating but lower our 12-month price target to C$0.30 (from C$0.35), representing approximately 88% upside from C$0.16 (as of 2026-06-02, per Investing.com / TradingView). The quarter was soft on the top line and slipped to a small net loss, but the balance sheet was transformed, gross margin expanded to a multi-year high, and the strategic narrative (Government & Defense, SNAPS, AIoT) advanced on every front. Our initial coverage on NVI was published May 4, 2026, framing Novra as a deeply mispriced satellite-infrastructure and government-SATCOM business coming off a large FY2025 turnaround, with SNAPS providing strategic capital at a 143% premium. Q1 tests the lumpiness of the model without breaking the thesis. ## What Changed - Revenue: C$0.89M, down 36% YoY from C$1.39M, on thin backlog carried into the year. Product revenue fell 56% to C$430K; service revenue grew 12% to C$463K and was the larger line for the first time, at 52% of the mix. - Profitability: Swung to a net loss of C$74K (from net income of C$481K in Q1 2025). Adj. EBITDA collapsed to C$45K from C$726K — still positive, but a fraction of the prior year on the lower revenue base. - Gross margin: Expanded 13.5 points to 57.2% (from 43.7%), driven by the richer service/product mix — the structural margin story strengthened even as volume dipped. - Balance sheet — the real story: Cash jumped to C$4.1M (from C$1.5M at year-end) as SNAPS advanced C$4.35M for shares. Shareholders' equity flipped positive to C$1.6M (from –C$2.8M). The IMT related-party promissory note (CEO-controlled) was repaid in full, with C$100K of payables forgiven. Quick ratio improved to 2.94:1 (from 1.49:1); working capital ratio to 3.53:1 (from 2.07:1). - SNAPS becomes a Control Entity: SNAPS has requested conversion of the US$3.7M received to date into ~14.8M shares at C$0.34 — more than 20% of shares outstanding, making it a new Insider and Control Entity. TSX-V has approved the US$0.5M tranche (no vote needed) and the US$3.2M tranche (subject to shareholder approval). A shareholder meeting is set for June 26, 2026 . A new agreement commits a further US$5.3M by September 30, 2026. - AIoT target named: Lilikoi Technologies Inc. identified as the AIoT partner, with discussions underway on a potential merger or acquisition — the optionality flagged in May now has a name attached. - Government & Defense formalized: New Government & Defense division launched at CANSEC 2026, alongside delivered U.S. Space Force orders, a completed SATCOM modernization for a prime contractor, and growing MAP Pro Data GBS receiver adoption (now STIG-compliant). ## Thesis Check Reviewing each of the five original pillars: - Pillar 1 — FY2025 Turnaround Is Large and Real (INTACT, TESTED): The turnaround was always about structural profitability, not linear quarterly growth. Margin expanded to 57.2% and opex discipline held (G&A –9%, S&M –14%), but thin backlog produced a small net loss. Management has consistently warned that revenue fluctuates sharply quarter to quarter; this is that volatility, not a reversal. - Pillar 2 — Government and Defence: A Growing Anchor (STRENGTHENED): A dedicated division now exists, U.S. Space Force orders shipped, a SATCOM prime modernization was delivered, and GBS receiver demand is building. This is the clearest area of momentum in the quarter. - Pillar 3 — Cortex, MISTiQ, and the Recurring Revenue Build (STRENGTHENED): Service revenue rose 12% and outweighed product revenue for the first time, with security-update services called out as a growth area. The recurring-revenue pivot is showing up in the numbers. - Pillar 4 — SNAPS: Strategic Capital and AIoT Optionality (STRENGTHENED, WITH NEW COST): Capital arrived (C$4.1M cash, equity positive), Lilikoi was named, and US$5.3M more is committed. But the optionality now carries a governance price — SNAPS crosses 20% to become a Control Entity, with the June 26 vote pending. - Pillar 5 — Valuation: ~3x Adj. EBITDA for a Profitable Business (INTACT): At C$0.16 the EV of ~C$3.6M is still ~3.9x LTM Adj. EBITDA and 0.73x LTM revenue. The trailing EBITDA denominator shrank as the strong Q1 2025 rolled off, which is why we trim the target — but the cheapness is intact. ## Updated Financials | Metric (C$000s) | Q1 2025 | Q1 2026 | YoY Change | | Total Revenue | 1,392 | 893 | -36% | | Product | 978 | 430 | -56% | | Service | 414 | 463 | +12% | | Gross Profit | 609 | 511 | -16% | | Gross Margin | 43.7% | 57.2% | +13.5 pts | | Operating Expenses | 768 | 786 | +2% | | Adj. EBITDA | 726 | 45 | -94% | | Net Income / (Loss) | 481 | (74) | NM | | Balance Sheet (C$000s) | Dec 31, 2025 | Mar 31, 2026 | Change | | Cash & Equivalents | 1,467 | 4,110 | +C$2.6M | | Shareholders' Equity | (2,767) | 1,616 | Turned positive | | Related-Party Note | 1,411 | 0 | Repaid in full | | Quick Ratio | 1.49:1 | 2.94:1 | Improved | | Working Capital Ratio | 2.07:1 | 3.53:1 | Improved | Three months ended March 31. Adj. EBITDA is a non-IFRS measure. Quick and working-capital ratios exclude related-party and deferred-revenue balances, per company definition. ## Updated Valuation We keep our framework but lower the base case. LTM Adj. EBITDA now sits near C$0.92M (versus the C$1.60M FY2025 figure that anchored our May target) as the strong Q1 2025 quarter rolled off. At C$0.16 and ~C$5.3M market cap, Novra carries an enterprise value of roughly C$3.6M — about 3.9x LTM Adj. EBITDA and 0.73x LTM revenue, still among the cheapest profitable microcaps we track. Our revised C$0.30 target applies ~8x to a normalized FY2026E Adj. EBITDA of roughly C$1.0–1.2M (between the depressed trailing figure and the FY2025 peak) plus net cash. The SNAPS conversion price of C$0.34 remains an independent strategic reference point well above today's level. | Scenario | Basis | Price / Share | vs. Current | | Bear Case | 4x normalized Adj. EBITDA | C$0.15 | ~-6% | | Base Case | 8x FY2026E Adj. EBITDA + net cash | C$0.30 | ~+88% | | Bull Case | 1.3x FY2026E revenue | C$0.42 | ~+163% | | SNAPS Reference | Conversion price | C$0.34 | ~+113% | ## Risk Update - Control & dilution — SNAPS (HIGH, escalated): Conversion of US$3.7M into ~14.8M shares takes SNAPS above 20%, creating a new Insider and Control Entity ahead of the June 26, 2026 shareholder vote. A further US$5.3M is committed by September 30. Minority holders cede effective control; related-party transaction scrutiny rises materially. - Revenue lumpiness / order visibility (HIGH, demonstrated): Q1 made the backlog-dependence concrete — a 36% revenue swing on timing alone. Management explicitly expects continued quarter-to-quarter volatility, so single-quarter results should not be annualized. - Macro / tariff / geopolitical (MEDIUM): Tariff turmoil and the Iran conflict (began February 2026) are delaying customer capital commitments, pressuring near-term revenue and gross profit. - Credit-facility contraction (LOW): The RBC facility was cut to C$380K (from C$1.2M); largely offset by the SNAPS cash inflow, but a thinner external backstop. - Microcap liquidity (MEDIUM): ~C$5M market cap, no analyst coverage, and a tight float make the stock vulnerable to wide spreads and volatility. ## Conclusion Q1 was the quarter the thesis was always going to have to survive: a low-backlog start to the year that exposes how lumpy Novra's revenue really is. It survived. The model slipped to a token loss, but gross margin hit a multi-year high, the balance sheet went from negative equity and related-party debt to C$4.1M cash and positive equity, and the strategic engine — Government & Defense, recurring services, the named Lilikoi AIoT path — moved forward rather than back. The cost is governance: SNAPS is about to control the company, and the June 26 vote is the event to watch. We trim the target to reflect a smaller trailing earnings base, not a broken thesis. At C$0.16 per share and a ~C$5.3M market cap — under 4x LTM Adj. EBITDA with net cash on the books and a strategic backer paying C$0.34 — the asymmetry that drew us in remains. We maintain our Spec. Buy rating with a revised C$0.30 price target. --- # IC Group Holdings Inc. (TSXV: ICGH) — Equity Research - URL: https://microcapresearch.ca/reports/icgh-ic-group-holdings-inc-2026-q1update - PDF: https://microcapresearch.ca/reports/icgh-ic-group-holdings-inc-2026-q1update.pdf - Report ID: ICGH-2026-05-Q1update - Published: 2026-05-28 - Sector: Marketing Technology - Rating: Spec. Buy - Price target: C$1.10 - Price at publication: C$0.46 - Implied upside: +139% - Market cap: C$18.9M - Status: SUPERSEDED > **This May 28, 2026 report is no longer current. Microcap Research published a newer IC Group Holdings Inc. (ICGH) update on Aug 27, 2026, which reaffirmed the Spec. Buy rating at C$1.10.** Current report: https://microcapresearch.ca/reports/icgh-ic-group-holdings-inc-2026-q2update **Bottom line:** Microcap Research rates IC Group Holdings Inc. (TSXV: ICGH) Spec. Buy with a 12-month price target of C$1.10, about 139% above the C$0.46 share price at publication on May 28, 2026. Market capitalisation at publication: C$18.9M. **Thesis:** Q1 2026 validated the operating-leverage thesis: Adjusted EBITDA jumped 300% to C$0.67M on 29% organic-led revenue growth, and EBITDA turned positive. The stock drifted to C$0.46, leaving ICGH cheaper (~0.85x LTM EV/Revenue) than at initiation. IC Engage strengthened; IC Mobile margin is the watch item. Maintain Spec. Buy, C$1.10. ## Key statistics - Market Cap: C$18.9M - EV/Revenue (LTM): ~0.85x - EV/Adj. EBITDA (LTM): ~12.8x - Revenue (Q1 2026): C$7.8M (+29%) - Adj. EBITDA (Q1 2026): C$0.67M (+300%) - Gross Margin (Q1 2026): 43% ## Update Summary This update follows IC Group's Q1 2026 results (three months ended March 31, 2026), released May 27, 2026, and the May 28 investor webinar. We maintain our Speculative Buy rating and maintain our 12-month price target of C$1.10, representing approximately 139% upside from C$0.46 (as of 2026-05-28). The quarter validated the operating-leverage leg of our thesis — Adjusted EBITDA rose 300% to C$0.67M and consolidated EBITDA turned positive — while the stock has drifted lower, leaving ICGH cheaper today (~0.85x LTM EV/Revenue) than at our initiation. Our initial coverage on ICGH was published May 7, 2026, framing IC Group as an undiscovered, sub-1x-revenue MarTech compounder with Tier-1 messaging infrastructure, a scaling sports-tech SaaS platform (Fannex), and a high-margin specialty insurance book. Q1 is the first earnings print since initiation, and it tests the growth-and-margin trajectory rather than the structure of the business. ## What Changed - Revenue: +29% YoY to C$7.8M, with approximately 86% of the growth organic. Growth moderated from the FY2025 pace of +50%, but that prior figure was inflated by the IC Mobile wholesale ramp and the Fannex acquisition; an 86%-organic +29% is a cleaner read on underlying demand. - Adjusted EBITDA inflection: +300% YoY to C$0.67M, and up roughly 3% sequentially versus Q4 2025. Consolidated EBITDA swung positive to C$0.40M from C$(1.61)M a year ago — the clearest evidence yet of the operating leverage we underwrote. - Net loss narrowed to C$(0.33)M from C$(2.09)M, but we flag honestly that most of that improvement reflects the absence of the ~C$1.06M reverse-takeover listing expense booked in Q1 2025, not a like-for-like operating swing. - IC Engage strengthened: revenue +36% to C$3.7M at a ~66% gross margin (gross profit +32% to ~C$2.4M). The Fannex platform now spans 95 professional teams, up from 85 a year ago; 81% of the segment's growth was organic with 19% from continued Fannex integration. - IC Mobile margin pressure: revenue +27% to C$3.6M (entirely organic), but gross margin compressed to ~17% on lower-margin wholesale messaging mix, so gross profit grew only ~5% to ~C$0.61M. - IC Insurance soft: revenue flat at ~C$0.46M and gross profit down 11% to ~C$0.26M amid industry premium compression as the book rebalances between contingency and liability. - Balance-sheet housekeeping: C$175K of shareholder debt was converted to equity at C$0.50/share in January, and the remaining C$225K was extended to March 31, 2027. Cash ended at C$3.4M (down from C$4.8M at year-end) on a deferred-revenue drawdown and deleveraging; management guided cash lower again at Q2-end on seasonality before replenishing in Q3. ## Thesis Check Reviewing each of the five original pillars: - Pillar 1 — Exceptional Organic Growth at Scale (INTACT, moderating): +29% revenue at 86% organic confirms the engine still runs, though the growth rate stepped down from the FY2025 headline. The Adjusted EBITDA inflection is the more important validation — growth is now converting to profitability. - Pillar 2 — IC Mobile: Defensible Tier-1 Infrastructure (INTACT): The segment grew 27% organically and the Tier-1 aggregator position is unchanged, with continued investment in MMS and RCS/RBM. The watch item is margin, not defensibility — wholesale mix is diluting segment economics. - Pillar 3 — Fannex: A SaaS Platform at Inflection (STRENGTHENED): Team count rose to 95 (from 85 YoY), IC Engage gross profit grew 32% to ~C$2.4M at a 66% margin, and the cross-sell narrative is intact. This is the pillar that advanced most in the quarter. - Pillar 4 — Deeply Discounted Valuation (STRENGTHENED): The dislocation widened. With the stock at C$0.46 and LTM revenue now ~C$28.7M, EV/Revenue has compressed to ~0.85x from ~0.94x at initiation — the company is cheaper despite a quarter of growth and a profitability inflection. - Pillar 5 — Multiple Near-Term Catalysts (INTACT): RCS/RBM investment continues, the Players Health insurance assets are integrating, and the shareholder-debt conversions modestly de-risk the balance sheet. No fresh update on the potential TSX uplisting or the US$7.8M enterprise renewal this quarter. ## Updated Financials | Metric | Q1 2025 | Q1 2026 | YoY Change | | Revenue (C$M) | $6.0M | $7.8M | +29% | | Gross Profit (C$M) | $2.7M | $3.3M | +22% | | Gross Margin | 45% | 43% | -2 pts | | Adj. EBITDA (C$M) | $0.17M | $0.67M | +300% | | Net Loss (C$M) | $(2.09)M | $(0.33)M | improved | Q1 2025 net loss included a ~C$1.06M non-recurring listing expense from the February 2025 reverse takeover. ARR held at approximately 68% of revenue, consistent with the prior-year period. ## Updated Valuation Our valuation framework is unchanged: EV/Revenue, reflecting the comparability of revenue multiples across MarTech and CPaaS peers (Bandwidth, Sinch, and digital-promotions/sports-tech names that trade at 1.5x–4x trailing revenue). We roll the base to a forward FY2026 revenue estimate of ~C$32.5M, derived conservatively off the Q1 run-rate. Applying our base-case 1.5x multiple, net of ~C$5.5M net debt across ~41M shares, supports our maintained C$1.10 target. The scenario prices below are unchanged in basis; only the “vs. current” column moves with the lower share price. | Scenario | EV Multiple (fwd Rev) | Price / Share | vs. Current | | Bear Case | 1.0x EV/Rev | C$0.66 | +43% | | Base Case | 1.5x EV/Rev | C$1.10 | +139% | | Bull Case | 2.0x EV/Rev | C$1.45 | +215% | ## Risk Update - Gross Margin Compression (MEDIUM, now playing out): The risk we flagged at initiation is materializing — IC Mobile gross margin fell to ~17% on wholesale mix, pulling consolidated margin to 43%. The offset is that IC Engage's high-margin mix is growing faster, but the consolidated trend bears watching. - Going Concern / Leverage (HIGH, modestly easing): The C$175K debt-to-equity conversion and the extension of the remaining C$225K to March 2027 improve near-term flexibility, and shareholders' equity held at ~C$7.2M. Bank indebtedness of ~C$7.3M remains the structural overhang. - Seasonal Cash Drawdown (MEDIUM, new framing): Management explicitly guided cash lower again at the end of Q2 before a Q3 replenishment. A soft Q2 cash balance should not be read as deterioration. - Illiquidity / Small-Cap Risk (HIGH, unchanged): ~C$19M market cap, no formal sell-side coverage, thin TSXV volume. Not suitable for large positions. ## Conclusion Q1 2026 was the quarter the thesis needed to show profitability following the growth, and it did: Adjusted EBITDA tripled, EBITDA turned positive, and IC Engage's SaaS-led mix continued to expand at a 66% margin. The two honest caveats are that headline growth moderated to +29% and that IC Mobile's margin compression — the exact risk we underwrote — is now visible in the consolidated numbers. Neither breaks the structure of the business. At C$0.46 per share and a ~C$18.9M market cap, the market is paying ~0.85x LTM revenue for a business that just demonstrated operating leverage, with the RCS opportunity, Fannex's 95-team footprint, and the insurance Coverholder licensing still ascribed essentially no value. The dislocation is wider than at our initiation three weeks ago. We maintain our Speculative Buy rating with a C$1.10 price target. --- # East Side Games Group Inc. (TSX: EAGR) — Equity Research - URL: https://microcapresearch.ca/reports/eagr-east-side-games-group-inc-2026-q1 - PDF: https://microcapresearch.ca/reports/eagr-east-side-games-group-inc-2026-q1.pdf - Report ID: EAGR-2026-05-Q1 - Published: 2026-05-20 - Sector: Technology / Mobile Gaming - Rating: Spec. Buy - Price target: C$0.24 - Price at publication: C$0.095 - Implied upside: 153% - Market cap: C$10.4M - Status: SUPERSEDED > **This May 20, 2026 report is no longer current. Microcap Research has since changed its rating on East Side Games Group Inc. (EAGR) from Spec. Buy to Avoid, with a C$0.06 price target, in the Aug 14, 2026 update.** Current report: https://microcapresearch.ca/reports/eagr-east-side-games-group-inc-2026-q2update **Bottom line:** Microcap Research rates East Side Games Group Inc. (TSX: EAGR) Spec. Buy with a 12-month price target of C$0.24, about 153% above the C$0.095 share price at publication on May 20, 2026. Market capitalisation at publication: C$10.4M. **Thesis:** Q1 2026 confirms the turnaround thesis is structurally intact — Adj. EBITDA margin expanded 330 bps YoY to 14% despite a deliberate 32% revenue cut driven by UA discipline. Management publicly committed to eliminating all bank debt by year-end 2026, direct-to-consumer revenue tripled to 11% of IAP in a single quarter, and Trailer Park Boys Match launched with >40% Day-1 retention. We lower our price target to C$0.24 on revised base-case EBITDA of C$7.0M, but the risk/reward at C$0.095 — 2.6x annualised Q1 EBITDA — remains asymmetric. ## Key statistics - Market Cap (FD): C$10.4M - EV / 2026E Adj. EBITDA: ~2.2x - Revenue (Q1 2026): C$12.45M - Adj. EBITDA (Q1 2026): C$1.74M - Adj. EBITDA Margin: 14.0% - D2C Mix (IAP): 11% ## Executive Summary East Side Games Group Inc. (TSX: EAGR) reported Q1 2026 results on May 14, 2026, confirming that the hard profitability pivot initiated in December 2025 is producing real structural margin improvement — even as reported revenue declined sharply. Revenue of C$12.45M fell 32% year-over-year, a direct and deliberate consequence of tightening the user acquisition (UA) return-on-ad-spend (ROAS) window from 365 days (FY2025 peak) to 30 days — the most conservative stance the Company has ever operated under. Adjusted EBITDA of C$1.74M (14.0% margin) represents a 330-basis-point improvement over Q1 2025's 10.7% and a dramatic recovery from Q3 2025's -14.8% trough. The share price has drifted further to C$0.095 since our May 9 initiation, widening implied upside to 153% against our revised C$0.24 price target. Three incremental developments strengthen the long-term thesis beyond the pure margin story: direct-to-consumer (D2C) revenue tripled from 3% to 11% of in-app purchase (IAP) revenue in a single quarter, reducing platform fee leakage from 30% to 5–10% on that volume; Trailer Park Boys Match launched March 17 with paid cohort Day-1 retention above 40% (versus industry average of 25–30%); and management made an unambiguous public commitment on the May 14 earnings call to eliminate all remaining bank debt by December 31, 2026 — a harder target than anything in the written filings. The going-concern note remains technically required until covenants are formally cured, but the C$3.6M private placement announced in May (with Director Derek Lew personally writing a C$2M director loan plus C$1M PP subscription) has materially reduced the acute solvency risk flagged at initiation. The report is not without blemish. Cash of C$163K at March 31 is critically thin, the Truly Social Games trial commenced May 25 with no provision booked, and management notably omitted any verbal reaffirmation of the full-year revenue guide (C$50–56M) during the earnings call — while explicitly reaffirming that Adj. EBITDA margin is "on pace with guidance." At Q1's revenue run-rate of C$12.45M, full-year revenue annualizes to approximately C$50M — the floor of guidance — implying no sequential improvement is currently assumed. We take a conservative stance and revise our base-case 2026E Adj. EBITDA to C$7.0M (from C$8.75M midpoint at initiation) and lower our 12-month price target to C$0.24 from C$0.30. The Speculative Buy rating is maintained. We maintain our Speculative Buy rating and revise our 12-month price target to C$0.24 (from C$0.30 at initiation on May 9, 2026), representing approximately 153% upside from the current price of C$0.095. The Q1 2026 results confirm margin expansion is real and structural, with D2C mix acceleration and the Google fee reduction (effective June 30) providing two additional visible profit tailwinds not reflected in the current valuation. ## Q1 2026 vs. Initiation Thesis — What Changed This report is a quarterly update to our May 9, 2026 initiation. The core thesis — a recapitalized free-to-play mobile publisher with a proven profitability playbook, trading at a deep discount to peers — remains intact. The following table summarises the key changes since initiation: | Item | At Initiation (May 9) | Post-Q1 (May 20) | Direction | | Share price | C$0.110 | C$0.095 | -14% | | Price target | C$0.30 | C$0.24 | Revised down | | Implied upside | 173% | 153% | Still asymmetric | | 2026E Adj. EBITDA (base) | C$8.75M | C$7.0M | More conservative | | Debt elimination commitment | Aspiration (written MD&A) | Public CEO commitment (earnings call) | Stronger | | D2C as % of IAP | ~3% (Q4 2025) | 11% (Q1 2026) | Accelerating | | TSG litigation | Trial date set (May 2026) | Trial commenced May 25 | Active binary risk | | Cash on hand | Not yet reported | C$163K at Mar 31 | Critically thin | | TPB Match | Not yet launched | >40% D1 retention, C$0.60 ARPDAU | Encouraging early data | ## Company Overview ESGG is a Vancouver-based free-to-play mobile gaming publisher operating a portfolio of 14+ live-service titles through two studios — Eastside Games Inc. ("ESG") and LDRLY (Technologies) Inc. — with approximately 110 employees. The Company monetizes through in-app purchases of virtual goods (74.5% of Q1 2026 revenue) and in-game advertising (25.5%), distributed via Apple App Store and Google Play globally, with concentration in North America and Europe. - Licensed IP portfolio (~80% of revenue): Trailer Park Boys, RuPaul's Drag Race, The Office, Star Trek: Lower Decks, Doctor Who, Power Rangers, AEW, Squishmallows, Cheech & Chong. Multi-year licensing deals with NBC Universal, CBS Viacom, BBC Studios, Hasbro, World of Wonder, and Jazwares. - Owned IP (~20% of revenue): Bud Farm and Milk Farm franchises carrying no royalty obligations. Bud Farm Idle Tycoon has been live for seven-plus years. - GameKit platform (licensing optionality): Proprietary game development framework licensed externally to partner studios. Three of the top five revenue titles in the last four years are GameKit products. The Q1 2026 operating model reflects a Company in deliberate contraction — sacrificing top-line users to recover margin. DAU of 145,581 (-30.5% YoY) and MAU of 518,000 (-39.4% YoY) reflect UA pullback, not product failure. ARPDAU of C$0.95 (-3.4% YoY) confirms the retained user base continues to monetize at near-prior-year levels. The DAU/MAU stickiness rate rose to 28.1% (+14.7% YoY) — meaning the users who remained became more habitually engaged, a counterintuitive quality improvement inside the contraction. ## Investment Thesis — Five Pillars ### 1. Margin Expansion Is Structural, Not Cyclical The most important number in the Q1 2026 report is not revenue — it is Adj. EBITDA margin of 14.0%. This is 330 basis points above Q1 2025's 10.7% margin on C$6.1M less revenue, demonstrating that the cost restructuring has genuinely changed the economics of the operating model. CFO Chan confirmed on the earnings call that Q1's margin is "on pace with our guidance" — the clearest reaffirmation management offered on the annual Adj. EBITDA range of C$7.5–10M. Three permanent structural changes underpin the margin shift. First, the reduction in force, project cancellations, and in-housing of live operations (previously outsourced to Night Garden) delivered approximately C$4M in annualized operating savings — visible in Q1 G&A of C$3.28M versus C$4M+ run-rates in H1 2025. Second, tightening the ROAS window to 30 days eliminated loss-making UA spend that diluted margins throughout 2025. Third, R&D expense fell 70% YoY to C$217K, reflecting the leaner post-RIF team. The C$1.14M in one-time charges recorded in Q1 (Night Garden exit C$594K, TSG litigation C$228K, severance C$322K) are expected to largely not recur in Q2 — adding approximately 9 percentage points of margin tailwind on a clean-quarter basis. ### 2. D2C and Google Fee Reduction Are Compounding Profit Tailwinds The single most underappreciated development in the Q1 cycle is the acceleration of direct-to-consumer (D2C) revenue, which CPO Wagner disclosed tripled from 3% to 11% of IAP revenue quarter-over-quarter. D2C routes player payments through ESGG's own payment rails at a 5–10% processor fee rather than through Apple/Google at 30% — a 20–25 percentage point improvement in net margin on that revenue slice. On Q1's C$9.3M of IAP revenue, 11% D2C penetration generated approximately C$1M in D2C revenue, saving roughly C$200K in platform fees in the quarter alone. Wagner guided further D2C mix gains in Q2 as successful A/B test results roll across the full portfolio. Separately, Google's new tiered platform fee structure (10–25%, down from 30%) takes effect June 30, 2026. All ESGG titles are tracking toward compliance ahead of that deadline, and management confirmed an expected C$500K per year in incremental profit — a clean, recurring contribution beginning in Q3 2026. Together, these two platform economics improvements could contribute C$700K–C$1M of incremental annualised EBITDA relative to the legacy cost structure. ### 3. Balance Sheet De-Risking Has Advanced — Debt Elimination Is Now a Public Commitment The going-concern note in the Q1 2026 financial statements is required under IFRS given the covenant history, but the practical solvency picture has improved materially since initiation. Director Derek Lew drew a C$2M personal director loan in Q1 2026, enabling ESGG to repay Bank Facility #3 (~C$1.58M) in full on April 30, 2026 — satisfying the lender's condition for maintaining access to remaining credit facilities. The C$3.6M private placement provides a further cash injection that, once closed, reduces pro forma net debt from C$6.6M to approximately C$3M. More significantly, CEO Bailey opened the May 14 earnings call with a public commitment to eliminate all remaining bank debt by December 31, 2026. For a CEO with a >50% equity stake, a public debt-elimination commitment implies confidence in H2 cash generation that the appropriately cautious written filings cannot articulate. If achieved, pro forma year-end EV at current prices would be approximately C$10.4M against C$7M+ Adj. EBITDA — roughly 1.5x on a debt-free basis, an extreme discount to any reasonable mobile gaming comparable. ### 4. Trailer Park Boys Match Shows Genuine Product Quality Trailer Park Boys Match launched globally on March 17, 2026. CPO Wagner disclosed two hard metrics on the earnings call: paid cohort Day-1 retention above 40% and ARPDAU averaging approximately C$0.60. D1 retention of 40%+ is meaningfully above the casual mobile industry average of 25–30%, indicating the product has genuine engagement hooks beyond paid traffic. ARPDAU of C$0.60 is below the mature portfolio average of C$0.95 but typical for a newly launched title before monetization layers are fully tuned. The game is built on the same IP as Trailer Park Boys: Greasy Money, which has attracted more than 10 million players and remains profitable nearly a decade after launch — providing a validated audience and credible long-tail reference point. ### 5. Valuation Remains Distressed at C$0.095 At C$0.095 per share with approximately 109M basic shares outstanding (143M fully diluted), EAGR's enterprise value is approximately C$19.5M (market cap ~C$10.4M plus net debt ~C$6.6M, partially offset by PP proceeds in-transit). Against Q1 annualised Adj. EBITDA of C$6.96M, the current valuation implies approximately 2.8x — still materially below the Western mobile gaming peer group median of 4–5x forward EV/EBITDA. The share price has declined 14% since our initiation at C$0.11, meaning the same fundamentals are available at a lower price than when we initiated. If Q2–Q4 deliver sequential Adj. EBITDA improvement — supported by disappearing one-time items, further D2C gains, and Google fee reduction from Q3 — the forward multiple compresses further from an already undemanding base. ## Financial Summary | Metric | FY2025 | Q1 2025 | Q1 2026 | YoY Change | | Revenue (C$M) | 77.58 | 18.54 | 12.45 | -32.8% | | Gross Profit (C$M) | 47.67 | 11.04 | 7.46 | -32.4% | | Gross Margin | 61.4% | 59.5% | 59.9% | +40 bps | | Adj. EBITDA (C$M) | 0.79 | 1.99 | 1.74 | -11.3% | | Adj. EBITDA Margin | 1.0% | 10.7% | 14.0% | +330 bps | | Net Loss (C$M) | (18.94) | (0.62) | (3.62) | n/m | | DAU | 209K avg | 209K | 145,581 | -30.5% | | ARPDAU | C$1.02 | C$0.98 | C$0.95 | -3.4% | | DAU/MAU stickiness | 25.0% | 24.5% | 28.1% | +14.7% | | Net Debt (C$M) | 4.9 | — | 6.6 | n/m | Net loss in Q1 2026 includes a C$2.20M non-cash deferred tax asset (DTA) write-down with zero cash impact — the write-down reflects accounting conservatism given the going-concern note, not an economic loss. Adj. EBITDA adds back depreciation (C$1.94M), SBC, one-time charges (C$1.14M), and the DTA write-down. Net debt elevated temporarily due to director loan; partially repaid post-quarter with PP proceeds. | Quarterly (C$M) | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | | Revenue | 18.54 | 19.22 | 20.05 | 19.76 | 12.45 | | Gross Profit | 11.04 | 11.93 | 12.49 | 12.20 | 7.46 | | Adj. EBITDA | 1.99 | 1.55 | (2.96) | 0.29 | 1.74 | | Adj. EBITDA Margin | 10.7% | 8.1% | (14.8%) | 1.5% | 14.0% | Q1 2026 margin of 14.0% is the highest in five quarters, achieved on the lowest absolute revenue base. One-time charges of C$1.14M should largely not recur in Q2, providing a natural margin step-up. ## Valuation We revise our valuation using a more conservative base-case 2026E Adj. EBITDA of C$7.0M, reflecting Q1 tracking the floor of guidance rather than the midpoint, and management's decision not to explicitly reaffirm the revenue guide on the call. We use the current share price of C$0.095, fully diluted shares of approximately 143M (post-financing, including all warrants), and pro forma net debt of approximately C$3M post-PP close. Western mobile gaming peers trade at approximately 4.7x forward EV/EBITDA; we apply a 4.5x base-case multiple reflecting EAGR's smaller scale and residual litigation risk. | Scenario | 2026E Adj. EBITDA | EV Multiple | Price / Share | vs. C$0.095 | | Bear Case | C$5.0M (guide miss) | 3.0x | C$0.07 | -26% | | Base Case | C$7.0M (low-end guide) | 4.5x | C$0.24 | +153% | | Bull Case | C$9.0M (guide midpoint) | 5.5x | C$0.38 | +300% | All scenarios use ~143M fully diluted shares and C$3M pro forma net debt post-PP close. The bear case notes that even at C$0.07 per share, EAGR's core live-service portfolio retains meaningful cash-flow liquidation value — the downside is not zero. ## Key Risks - Truly Social Games Litigation (HIGH): Trial commenced May 25, 2026 in British Columbia. ESGG spent C$228K on litigation in Q1 alone with no provision booked. An adverse outcome could produce a material cash judgment that the Company — with C$163K cash at quarter-end — cannot absorb without emergency financing. This is the single largest near-term binary risk and received zero airtime on the Q1 earnings call. - Revenue Trajectory (HIGH): Q1 revenue of C$12.45M annualises to C$49.8M — the absolute floor of the C$50–56M full-year guide — and management did not verbally reaffirm the revenue figure on the call. If Q2 does not show sequential stabilisation or improvement, the full-year number becomes unreachable without a step-change in UA spend that would undo the margin gains. Revenue growth and EBITDA margin expansion cannot simultaneously be maximised at a 30-day ROAS window. - Cash Position (HIGH): C$163K of cash at March 31, 2026. PP proceeds and the EDC facility (up to US$4M, referenced in the MD&A but not yet closed as of the report date) are the only near-term liquidity sources. Any delay in either closing would create an acute cash shortfall within weeks. - Severe Illiquidity / Microcap Risk (HIGH): Fully diluted market cap of approximately C$10.4M at C$0.095. Average daily trading volume in the low tens of thousands of shares. The four-month statutory hold on placement units creates a supply overhang in September 2026. Position sizing must reflect very limited exit liquidity. - Dilution and Off-Balance-Sheet Obligations (MEDIUM): Basic share count has risen from 76.9M to ~109M; fully diluted reaches ~143M on warrant exercise. The Bailey Ransen Family Trust escrow payable of C$3.1M (including interest) is an off-balance-sheet obligation not yet due but represents additional claims on future cash flow above the headline net debt figure. - DAU Stabilisation (MEDIUM): The stickiness rate improvement (28.1%) is encouraging but does not resolve whether the absolute DAU base will stabilise now that UA has been tightened. If DAU continues falling through Q2–Q3 without recovery, ARPDAU would need to increase commensurately — and there is limited historical precedent for portfolio-level ARPDAU expanding materially as titles mature. - Controlling Shareholder Concentration (MEDIUM): CEO Jason Bailey holds >50% of outstanding shares. Minority shareholders have limited ability to influence strategic decisions including future financings, asset sales, or a take-private transaction. All future share issuances are effectively at Bailey's discretion given his ability to provide written consent in lieu of a shareholder vote. ## Conclusion The Q1 2026 results are a Rorschach test for EAGR investors. Pessimists see C$12.45M of revenue — a third below a year ago — alongside a going-concern note, critically thin cash, and a live trial on material litigation. Optimists see the highest Adj. EBITDA margin in five quarters, a D2C inflection that tripled in a single quarter, a CEO who opened his earnings call by publicly committing to debt elimination, and a new product launch hitting retention metrics above industry averages. Both readings are internally consistent. The question is which one the market is pricing in twelve months from now. The pessimist case appears more than adequately reflected in the current share price of C$0.095 — 14% below our initiation price and now implying roughly 2.8x annualised Q1 Adj. EBITDA. At this level EAGR is priced for continued failure rather than a pivot that is producing visible and measurable margin improvement each quarter. The three near-term risks that could break the thesis (TSG litigation loss, cash shortfall, Q2 revenue miss) are real; the two that were most acute at initiation (covenant default, director/CEO support) have materially improved. The share price decline since initiation reflects the market's impatience, not new fundamental deterioration — on the contrary, the Q1 margin result and D2C acceleration are both incremental positives. We revise our 12-month price target to C$0.24 (from C$0.30) reflecting a more conservative C$7.0M 2026E Adj. EBITDA base case and a 4.5x multiple, and maintain our Speculative Buy rating. The TSG trial outcome and Q2 revenue trajectory are the two catalysts that will determine whether this target is achievable. Investors with existing positions should hold; new positions should be sized modestly given the liquidity constraints and binary litigation risk. This remains a piece of a speculative microcap basket, not a concentrated bet. --- # East Side Games Group Inc. (TSX: EAGR) — Equity Research - URL: https://microcapresearch.ca/reports/eagr-east-side-games-group-inc-2026 - PDF: https://microcapresearch.ca/reports/eagr-east-side-games-group-inc-2026.pdf - Report ID: EAGR-2026-05 - Published: 2026-05-09 - Sector: Technology / Mobile Gaming - Rating: Spec. Buy - Price target: C$0.30 - Price at publication: C$0.11 - Implied upside: 173% - Market cap: C$8.5M (basic) / C$15.8M (FD post-financing) - Status: SUPERSEDED > **This May 9, 2026 report is no longer current. Microcap Research has since changed its rating on East Side Games Group Inc. (EAGR) from Spec. Buy to Avoid, with a C$0.06 price target, in the Aug 14, 2026 update.** Current report: https://microcapresearch.ca/reports/eagr-east-side-games-group-inc-2026-q2update **Bottom line:** Microcap Research rates East Side Games Group Inc. (TSX: EAGR) Spec. Buy with a 12-month price target of C$0.30, about 173% above the C$0.11 share price at publication on May 9, 2026. Market capitalisation at publication: C$8.5M (basic) / C$15.8M (FD post-financing). **Thesis:** Distressed pricing on a recapitalized turnaround: stock is down 78% YoY, but management has issued explicit 2026 guidance of C$50–56M revenue and C$7.5–10M Adj. EBITDA — a >9x EBITDA reset versus FY2025's C$0.79M. A May 2026 C$3.5M private placement (with a director writing a C$1M cheque at the bottom and a >50% controlling CEO supporting dilution) repays RBC and clears the covenant overhang. Pro forma EV of ~C$17M values the business at just 2.0x guided 2026E Adj. EBITDA — versus 4.7x for Western mobile peers. ## Key statistics - Market Cap (FD): C$15.8M - EV / 2026E Revenue: 0.33x - EV / 2026E Adj. EBITDA: 2.0x - Revenue (FY2025): C$77.6M - Adj. EBITDA (FY2025): C$0.79M - Gross Margin: 61.4% ## Executive Summary East Side Games Group Inc. (TSX: EAGR) is a Vancouver-based free-to-play mobile gaming publisher operating a portfolio of 14+ live-service titles built around licensed IP — including Trailer Park Boys, RuPaul's Drag Race, The Office, Star Trek: Lower Decks, Doctor Who, Power Rangers, AEW, and Squishmallows — alongside owned IP such as Bud Farm and Milk Farm Tycoon. The Company generated C$77.6M in FY2025 revenue at a 61.4% gross margin, with 196,401 daily active users and ARPDAU of C$1.09. The setup is unusual. Stock is down approximately 78% over the past twelve months following a failed 2025 growth strategy that consumed cash, breached debt covenants, and culminated in a comprehensive operational reset. Management responded in December 2025 by executing a hard pivot back to profitability — the same playbook ESGG ran successfully in 2023, which produced C$11.6M Adj. EBITDA on C$83.1M revenue in FY2024. Management has now issued explicit FY2026 guidance of C$50–56M revenue and C$7.5–10M Adjusted EBITDA, implying a 15–18% margin and a >9x increase in Adj. EBITDA off a low FY2025 base. On May 1, 2026, the Company announced a C$3.5M private placement at C$0.11/unit (one share + one full warrant at C$0.14, three-year term), with director Derek Lew personally subscribing for C$1.0M. Proceeds will repay RBC indebtedness and reduce pro forma net debt to approximately C$1.6M, materially de-risking the going-concern overhang. CEO Jason Bailey, who controls more than 50% of outstanding shares, provided written consent in lieu of a shareholder vote — the strongest possible insider endorsement of the financing. We initiate coverage with a Speculative Buy rating and a 12-month price target of C$0.30, representing approximately 173% upside from current levels. Pro forma for the May 2026 financing, EAGR trades at roughly 2.0x management's 2026E Adj. EBITDA midpoint (C$8.75M) and 0.33x guided revenue — a multiple appropriate for a distressed liquidation, not a recapitalized company executing a proven turnaround playbook with insider capital alongside. ## Company Overview ESGG (formerly Leaf Mobile, formerly Caprice Business Development) is the parent of two operating studios — Eastside Games Inc. ("ESG") and LDRLY (Technologies) Inc. — and operates approximately 100 employees from headquarters in Vancouver, British Columbia. The Company monetizes through in-app purchases (IAP) of virtual goods and in-game advertising, distributed primarily through Apple's App Store and Google Play. Three Tier-1 platform partners and advertisers concentrate 75% of trade receivables. The Company's competitive moat — to the extent it has one — sits in three layers: - GameKit (proprietary platform): An internally-developed gametech framework that lets developers ship narrative-driven idle and match games faster and at lower cost than building from scratch. Three of the top five revenue-generating titles launched in the past four years are GameKit products, validating product-market fit. ESGG also licenses GameKit externally to partner studios. - Licensed IP catalog: A multi-year roster of partnerships including NBC Universal (The Office), CBS Viacom (Star Trek), BBC Studios (Doctor Who), Hasbro (Power Rangers), World of Wonder (RuPaul's Drag Race), Jazwares (Squishmallows), AEW, Cheech & Chong, and Trailer Park Boys. These deals are difficult for new entrants to replicate at micro-cap scale. - Owned IP (Bud Farm / Milk Farm franchises): No royalty obligations, full economic upside, and proven longevity — Bud Farm Idle Tycoon has been live for over seven years. Revenue mix is approximately 70% IAP / 30% advertising, distributed across iOS and Android globally with concentration in North America and Europe. The Company does not disclose individual title economics due to partner confidentiality, but ARPDAU of C$1.09 (Q4 2025, +12% Q/Q and +8.6% YoY) sits well above the casual mobile industry average and is a key indicator that the user base is high-quality even as DAU has compressed. ## Investment Thesis — Five Pillars ### 1. The 2026 Guidance Is Concrete and Implies a >9x EBITDA Reset Management issued formal FY2026 guidance on March 31, 2026: revenue of C$50–56M and Adjusted EBITDA of C$7.5–10M, implying a 15–18% margin. At the midpoint, Adj. EBITDA grows from C$0.79M (FY2025) to C$8.75M (FY2026E) — an order-of-magnitude reset rather than incremental improvement. Three concrete cost actions underpin the guide: First, a Q1 2026 reduction in force, project cancellations, and the in-housing of live operations on a core game (previously outsourced to Night Garden) — collectively expected to deliver approximately C$4M CAD in annualized operating savings. Second, a shortened user acquisition payback window from 365 days to 60 days, reducing speculative UA spend that drove the FY2025 cash burn. Third, off-platform payments (OPP) are now routing approximately C$1.0M of Q1 2026 revenue around Apple/Google's 30% platform fee — a 240% Q/Q increase that translated to C$0.24M of bottom-line benefit in a single quarter, with management guiding 10–15 percentage points of incremental margin on shifted volume. Critically, this is not the first time ESGG has executed this playbook. In Q3 2023 the Company pivoted from growth to profitability and delivered C$11.6M Adj. EBITDA on C$83.1M revenue in FY2024 — a 14% margin. The 2026 guidance midpoint (16.5%) sits modestly above that prior outcome, which is achievable on a smaller, restructured cost base. ### 2. The May 2026 Financing De-Risks the Solvency Overhang On May 1, 2026, ESGG announced a non-brokered private placement of 31,818,182 units at C$0.11 each — one common share plus one three-year warrant exercisable at C$0.14 — for gross proceeds of up to C$3.5M. Director Derek Lew personally subscribed for C$1.0M (9.09M units), and CEO Jason Bailey, who holds more than 50% of outstanding shares, provided written consent in lieu of a shareholder vote. Proceeds will be used primarily to repay Royal Bank of Canada indebtedness, reducing pro forma net debt from C$4.9M to approximately C$1.6M. This matters because Q4 2025 Funded Debt covenants were offside, and management was actively negotiating a tolerance letter with RBC — a clear going-concern flag at the time. Paying down RBC eliminates the most acute near-term risk to the equity, removes the threat of a forced liquidity event, and gives management runway to execute the operational pivot without a creditor renegotiation hanging over the business. The terms are dilutive — basic share count rises from 76.9M to ~110.1M (+43%), and fully diluted to ~143.2M (+86%) if all warrants and broker warrants are exercised. But dilution is what enabled the recap rather than a far worse outcome (rescue financing at deeper discount, or distressed asset sale). The C$0.11 unit price matched the market price; the C$0.14 warrant strike represents only a 27% premium to the placement price and a 2.5% discount to the five-day VWAP. ### 3. Insider Conviction Is Substantial The signal-to-noise ratio in the May 1 announcement is unusually high. A sitting director writing a personal C$1.0M cheque at C$0.11/share is approximately 60% of his pre-deal share value (he held 1.67M shares ≈ C$184K) being committed at the bottom. Post-deal, on a partially diluted basis Mr. Lew would hold 9.89% of the Company, rising to 16.84% on full warrant exercise — an unusually large position for a non-founding director. CEO Jason Bailey's >50% controlling stake is itself a material datapoint missing from most third-party coverage. Bailey sits in a position where he could have sought a take-private transaction at distressed prices; instead, he chose to support a public-market recapitalization that brings in outside capital alongside his own holdings. The willingness to accept dilution rather than pursue a privatization at C$0.11 implies management views the equity as materially undervalued at these levels. Insider buying at the bottom is among the most reliable contrary indicators in microcap investing — particularly when the buyer is putting up cash rather than receiving stock-based compensation. ### 4. The Core Portfolio Is a Real Cash-Generating Asset Outside of new game launches, ESGG's established live-service portfolio continues to generate profitable cash flow. CFO Jason Chan stated on the Q4 2025 call that the core portfolio operates at approximately 14% margins — consistent with the FY2024 corporate-level outcome and well above what the failed 2025 growth bets contributed. ARPDAU of C$1.09 and a 25.0% DAU/MAU stickiness rate indicate a loyal, monetizing user base. Q4 2025 saw a 12% Q/Q ARPDAU increase even as DAU softened. Three of the top five titles (RuPaul's Drag Race Superstar, The Office: Somehow We Manage, Milk Farm Tycoon) launched within the last four years, so this is not a portfolio entirely dependent on legacy hits — though 2017's Trailer Park Boys: Greasy Money and 2019's Bud Farm Idle Tycoon remain meaningful contributors. Two new Match-3 titles launched in 2025 (RuPaul's Drag Race Match Queen, June 2025; Squishmallows Match, September 2025), the former delivering the highest ARPDAU in the entire portfolio. The Company is also exploring connected-TV and PC/console-portable titles, opening optionality beyond mobile-only distribution. The decline in DAU (-11% YoY) reflects a discovery and acquisition problem in a saturated mobile market, not a product-quality problem. This is the precise issue the strategic pivot is designed to address by harvesting the existing portfolio rather than chasing new-user growth. ### 5. Valuation Is Distressed-Pricing for a Recapitalized Business At C$0.11 per share, EAGR's pro forma enterprise value (using ~143M fully diluted shares plus ~C$1.6M net pro forma debt) is approximately C$17.4M. That values the business at: - 0.22x trailing revenue (C$77.6M FY2025) - 0.33x guided 2026E revenue (C$53M midpoint) - ~2.0x guided 2026E Adj. EBITDA (C$8.75M midpoint) - ~22x trailing Adj. EBITDA (the metric the market is pricing off) The disconnect is between trailing and forward multiples. Western mobile gaming peers (per Equidam 2025 sector analysis) trade at approximately 4.7x forward EV/EBITDA. Diversified gaming companies trade at 13.8x. Stillfront trades at roughly 4–5x; Embracer Group at 5x. Even applying the lowest peer multiple (4.7x) to 2026E midpoint EBITDA implies an enterprise value of C$41M, more than 2x the current pro forma EV. EAGR is being priced as if 2026 guidance is fictional. The cost actions, OPP rollout, Google fee reduction (effective June 30, 2026, worth approximately C$0.5M annually), and prior-cycle execution evidence collectively suggest otherwise. ## Financial Summary | Metric | FY2024 | FY2025 | YoY Change | | Revenue (C$M) | 83.12 | 77.58 | -6.7% | | Gross Profit (C$M) | 50.77 | 47.67 | -6.1% | | Gross Margin | 61.1% | 61.4% | +30 bps | | Adj. EBITDA (C$M) | 10.10 | 0.79 | -92.2% | | Net Income / (Loss) (C$M) | (0.93) | (18.94) | n/m | | DAU (avg) | 234K | 209K | -10.7% | | ARPDAU | C$0.99 | C$1.02 | +3.0% | | Net Debt (C$M) | (7.6) | 4.9 | n/m | Note: FY2024 Adj. EBITDA figure of C$10.10M reflects the comparative as restated in the FY2025 audited financial statements (vs. C$11.63M originally reported in the FY2024 MD&A). FY2024 net debt is shown as a negative figure to indicate net cash position. | Quarterly (C$M) | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | | Revenue | 18.54 | 19.22 | 20.05 | 19.76 | | Gross Profit | 11.04 | 11.93 | 12.49 | 12.20 | | Adj. EBITDA | 1.99 | 1.55 | (2.96) | 0.29 | | Adj. EBITDA Margin | 10.7% | 8.1% | (14.8%) | 1.5% | Q3 2025 reflects peak UA investment ahead of the Squishmallows Match launch (September 1, 2025); Q4 returned to positive Adj. EBITDA as the strategic pivot took effect. ## Valuation We value EAGR on a forward EV/Adj. EBITDA basis, anchoring on management's stated 2026E guidance midpoint of C$8.75M. We use a fully diluted share count of approximately 143.2M (post-financing, post-warrant exercise) to be conservative on dilution, and pro forma net debt of approximately C$1.6M (after C$3.5M placement repays a portion of RBC indebtedness). Western mobile gaming peers including Stillfront, Embracer's mobile segment, and MAG Interactive currently trade at approximately 4.7x forward EV/EBITDA per available sector data; diversified gaming companies (Take-Two, Electronic Arts, NetEase) trade considerably higher at 9–14x. We apply a 5.0x multiple in our base case — a modest premium to the Western mobile median to reflect the recently de-risked balance sheet and credible cost-cut execution path, but a discount to diversified peers given EAGR's smaller scale, declining DAU, and the residual execution risk on guidance. | Scenario | Basis | Price / Share | vs. Current | | Bear Case | Guidance miss; 2.5x on C$4M EBITDA, +C$2M debt | C$0.04 | -64% | | Base Case | 5.0x on C$8.75M 2026E Adj. EBITDA midpoint | C$0.30 | +173% | | Bull Case | 6.0x on C$10M 2026E Adj. EBITDA high end | C$0.41 | +273% | | Strategic Reference | Insider warrant strike (Derek Lew, May 2026) | C$0.14 | +27% | Note: All scenarios use ~143.2M fully diluted shares. The bear case assumes 2026 Adj. EBITDA falls to approximately C$4M (mid-FY2024 level adjusted for smaller cost base), additional debt is taken on, and the market applies a distressed multiple. Even the bear outcome is not zero — the core portfolio retains liquidation/cash flow value. ## Key Risks - Guidance Execution Risk (HIGH): The entire investment case rests on management delivering 2026 Adj. EBITDA of C$7.5–10M against C$0.79M trailing. Cost cuts of C$4M annualized, OPP rollout, and Google's tiered fee reduction (effective June 30, 2026) are visible levers, but DAU has been declining double-digits YoY and 2026 revenue is guided down 28–36% from 2025. Margin must therefore expand from 1% to 15–18% on a smaller base. Management has executed this pivot once before (2023→2024), but a second miss would likely trigger covenant action and further dilution. - Truly Social Games Litigation (HIGH): Outstanding British Columbia litigation with Truly Social Games LLC has a trial date set for May 2026. While the U.S. District Court of Oregon dismissed TSG's parallel claim in December 2023, an adverse outcome in BC could result in material damages. Litigation costs already contributed to the Q4 2025 covenant breach. - Severe Illiquidity / Microcap Risk (HIGH): Pro forma fully diluted market cap is approximately C$15.8M with average daily trading volume in the low tens of thousands of shares. The four-month statutory hold on placement units will create a meaningful supply overhang in September 2026 when those shares become tradeable. Position sizing should be small, and exit liquidity is limited. - Continued Covenant Risk (MEDIUM): The May 2026 financing reduces but does not eliminate RBC exposure. Management has indicated it will request additional accommodations from RBC for Q2 2026 as restructuring continues, and a temporary debt increase is planned in Q1 2026 for severance and litigation costs. Any Q2 covenant denial would re-introduce solvency risk. - Platform Dependency (MEDIUM): Three Tier-1 platforms and advertisers concentrate 75% of receivables. While Apple and Google fee reductions are tailwinds in 2026, any material change in platform policies (algorithmic discoverability, IDFA-style privacy changes, terms of service) could compress the core portfolio's economics. The off-platform payment thesis itself depends on the persistence of recent court rulings — appellate reversals are possible. - Controlling Shareholder Concentration (MEDIUM): CEO Jason Bailey holds more than 50% of outstanding shares. While alignment is positive in the current setup, minority shareholders have limited ability to influence outcomes, including any future privatization, asset sale, or strategic transaction. Future financings could be structured at terms that further dilute minorities without independent shareholder approval. ## Conclusion EAGR is a binary microcap recapitalization story dressed up in a complicated narrative. Strip away the noise — the 2025 growth strategy that consumed cash, the covenant breach, the 80% drawdown, the 86% prospective dilution — and what remains is a recapitalized free-to-play mobile gaming business with C$77M of trailing revenue, real and demonstrably loyal users, a proven prior-cycle pivot to profitability, explicit forward guidance backed by visible cost-action levers, and a director writing a C$1M cheque at the bottom alongside a >50% controlling CEO who chose dilution over privatization. The bear case is real and we have not minimized it. Guidance execution is the entire thesis; a second miss after 2025 would be punishing, and the litigation tail is unresolved. But the share price is already discounting failure. At ~2.0x guided 2026E Adj. EBITDA — when even the lowest-quality Western mobile peers clear 4–5x — the market is pricing a liquidation that the May financing has substantially walked back. Insiders have separately demonstrated that they disagree with the market's assessment by deploying personal capital alongside outside subscribers at C$0.11 with warrants struck only modestly above that level. At C$0.11 per share and approximately C$15.8M fully diluted market cap, the market is granting EAGR no credit for the strategic pivot, no credit for OPP-driven margin expansion, no credit for Google's tiered fee reduction effective June 30, 2026, and no credit for the second-time execution of a playbook the team has run before. We rate EAGR Speculative Buy with a C$0.30 12-month price target. Given the illiquidity, controlling-shareholder dynamics, and outstanding litigation, position sizing should be modest — this is a piece of a microcap basket, not a concentrated bet. --- # IC Group Holdings Inc. (TSXV: ICGH) — Equity Research - URL: https://microcapresearch.ca/reports/icgh-ic-group-holdings-inc-2026 - PDF: https://microcapresearch.ca/reports/icgh-ic-group-holdings-inc-2026.pdf - Report ID: ICGH-2026-05 - Published: 2026-05-07 - Sector: Marketing Technology - Rating: Spec. Buy - Price target: C$1.10 - Price at publication: C$0.50 - Implied upside: 120% - Market cap: C$20.5M - Status: SUPERSEDED > **This May 7, 2026 report is no longer current. Microcap Research published a newer IC Group Holdings Inc. (ICGH) update on Aug 27, 2026, which reaffirmed the Spec. Buy rating at C$1.10.** Current report: https://microcapresearch.ca/reports/icgh-ic-group-holdings-inc-2026-q2update **Bottom line:** Microcap Research rates IC Group Holdings Inc. (TSXV: ICGH) Spec. Buy with a 12-month price target of C$1.10, about 120% above the C$0.50 share price at publication on May 7, 2026. Market capitalisation at publication: C$20.5M. **Thesis:** Canada's hidden MarTech compounder: 50% organic revenue growth, Tier-1 A2P messaging infrastructure, and a SaaS fan engagement platform covering 94 professional sports teams — all trading below 1x revenue with zero institutional coverage. ## Key statistics - Market Cap: C$20.5M - EV/Revenue: 0.94x - EV/Adj. EBITDA: ~18x - Revenue (FY2025): C$26.9M - ARR: C$18.3M - Gross Margin: 46% ## Executive Summary IC Group Holdings Inc. (TSXV: ICGH) is a Canadian marketing technology company delivering consumer engagement, mobile messaging, and specialty insurance solutions to over 150 enterprise customers across North America and Europe. The Company went public via reverse takeover in February 2025 and remains undiscovered by institutional sell-side coverage — a hallmark inefficiency in the TSX Venture universe. We initiate coverage with a Speculative Buy rating and a 12-month price target of C$1.10, representing approximately 120% upside from current levels. The Company trades at <1x trailing EV/Revenue while growing revenue 50% organically — an extraordinary dislocation for a recurring-revenue software business. ## Company Overview IC Group Holdings operates through three distinct but complementary segments, each with meaningful recurring revenue characteristics: - IC Engage (C$12.5M revenue, 68% gross margin): Digital promotions platform for Fortune 500 brands, plus the Fannex SaaS live-event fan engagement platform covering 94 professional sports teams across North America and Europe. Revenue driven by multi-year master service agreements and transactional fees. - IC Mobile (C$12.5M revenue, 21% gross margin): One of only three Tier-1 A2P messaging aggregators in Canada with direct carrier connections to Bell, Rogers, and Telus. Over 95% of segment revenue is Annual Recurring Revenue from enterprise SMS/MMS/RCS messaging. - IC Insurance (C$1.9M revenue, 65% gross margin): Specialty insurance solutions operating as a Lloyd's of London and Aviva Canada Coverholder. Products include event cancellation, prize indemnity, and crisis management for sports and entertainment. ## Investment Thesis — Five Pillars ### 1. Exceptional Organic Growth at Scale IC Group delivered 50% revenue growth in FY2025 to C$26.9M, of which approximately 95% was organic. IC Mobile grew 85% organically; IC Engage grew 31%. Adjusted EBITDA grew 66% to C$1.4M, and Q4 2025 Adj. EBITDA of C$0.63M was 55% higher than Q3 2025 — signaling accelerating momentum into FY2026. ### 2. IC Mobile: Defensible Tier-1 Infrastructure IC Mobile is one of only three Tier-1 A2P messaging aggregators in Canada — a structurally protected position requiring direct carrier interconnects that take years to establish. Over 95% of IC Mobile revenue is ARR. The RCS/RBM opportunity is a significant catalyst: Apple's 2024 announcement to support RCS unified the protocol across iOS and Android, potentially enabling higher per-message economics across 100% of the Canadian mobile market. ### 3. Fannex — A SaaS Platform at Inflection The February 2025 acquisition of Emotion Media (Fannex) brought a live-event fan engagement SaaS platform covering 94 professional sports teams. Acquired for effectively C$3.5M net of assumed debentures, the platform creates a powerful cross-sell: enterprise brands on IC Mobile can now be offered fan engagement campaigns at live events. IC Engage gross profit grew 8% sequentially in Q4 2025 to C$2.5M at a 72% margin. ### 4. Deeply Discounted Valuation ICGH trades at 0.94x trailing EV/Revenue — extraordinary for a company growing 50% with 68%+ recurring revenue. Comparable MarTech, CPaaS, and SaaS companies with similar growth profiles typically trade at 3x–8x revenue. The discount reflects TSXV listing with no institutional coverage, a going-concern audit note, and net losses from one-time public company transition costs — all temporal and/or addressable issues. ### 5. Multiple Near-Term Catalysts - New IC Mobile enterprise messaging contract (April 2026) adding up to C$1.0M incremental ARR - Renewal of five-year agreement with a major US enterprise technology company valued at up to US$7.8M cumulative through 2030 - RCS/MMS platform launch enabling higher-margin messaging formats - Players Health acquisition (October 2025) deepening IC Insurance's sports footprint - Potential TSX main board uplisting broadening institutional investor eligibility ## Financial Summary | Metric | FY2024 | FY2025 | YoY Change | | Revenue (C$M) | $17.9M | $26.9M | +50% | | Gross Profit (C$M) | $9.6M | $12.4M | +29% | | Gross Margin | 54% | 46% | -8 pts | | ARR (C$M) | ~$11.3M | $18.3M | +62% | | Adj. EBITDA (C$M) | $0.8M | $1.4M | +66% | | Net Loss (C$M) | $(5.5)M | $(3.5)M | 37% improvement | ## Valuation We use an EV/Revenue approach given early-stage Adj. EBITDA generation and the comparability of revenue multiples across MarTech and CPaaS peers. Our base case applies 1.5x FY2025 EV/Revenue, yielding a price target of C$1.10. Comparable public companies in CPaaS (Bandwidth, Sinch), digital promotions, and sports tech trade at 1.5x–4x trailing revenue. | Scenario | EV Multiple | Price / Share | vs. Current | | Bear Case | 1.0x EV/Rev | C$0.52 | ~flat | | Base Case | 1.5x EV/Rev | C$0.85–1.10 | ~+70–120% | | Bull Case | 2.0x EV/Rev | C$1.18 | ~+136% | | Analyst High | — | C$1.46 | ~+192% | ## Key Risks - Going Concern / Covenant Breach (HIGH): Senior lender has waived enforcement until January 1, 2027. Negative working capital of ~C$0.5M. Management expects resolution via operating cash flow. - Gross Margin Compression (MEDIUM): IC Mobile mix shift toward wholesale messaging is diluting consolidated gross margin from 54% to 46%. Carrier price increases not yet fully passed through. - Revenue Concentration (MEDIUM): US enterprise customers represent ~76% of revenue. Top customer relationships are large and multi-year but customer-level concentration exists. - Key Person Risk (MEDIUM): No key-man insurance. Success heavily tied to CEO Duncan McCready and small leadership team. - Illiquidity / Small Cap Risk (HIGH): ~C$20M market cap, no formal sell-side coverage, thin TSXV trading volume. Not suitable for large positions. ## Conclusion IC Group Holdings (TSXV: ICGH) is a rare find: a profitable-on-an-adjusted-basis, 50%-growth MarTech company trading below 1x revenue with defensible Tier-1 messaging infrastructure, a rapidly scaling SaaS platform across 94 professional sports teams, and a specialty insurance business generating high-margin recurring commissions. The going-concern note is the primary sentiment overhang, but the underlying lender relationship has been explicitly supportive and Q4 2025 momentum is strong. At C$0.50 per share and ~C$20.5M market cap, the market ascribes essentially zero premium for the RCS opportunity, Fannex's sports tech footprint, IC Insurance's Coverholder licensing, or any multiple expansion as the company matures. We rate ICGH Speculative Buy with a C$1.10 price target. --- # Novra Technologies Inc. (TSXV: NVI) — Equity Research - URL: https://microcapresearch.ca/reports/nvi-novra-technologies-inc-2026 - PDF: https://microcapresearch.ca/reports/nvi-novra-technologies-inc-2026.pdf - Report ID: NVI-2026-05 - Published: 2026-05-04 - Sector: Communications Equipment / Satellite Infrastructure - Rating: Spec. Buy - Price target: C$0.35 - Price at publication: C$0.14 - Implied upside: 150% - Market cap: C$4.7M - Status: SUPERSEDED > **This May 4, 2026 report is no longer current. Microcap Research kept its Spec. Buy rating on Novra Technologies Inc. (NVI) but lowered the price target from C$0.35 to C$0.30 in the Jun 2, 2026 update.** Current report: https://microcapresearch.ca/reports/nvi-novra-technologies-inc-2026-q1update **Bottom line:** Microcap Research rates Novra Technologies Inc. (TSXV: NVI) Spec. Buy with a 12-month price target of C$0.35, about 150% above the C$0.14 share price at publication on May 4, 2026. Market capitalisation at publication: C$4.7M. **Thesis:** A dramatic FY2025 turnaround — revenue +37%, gross margin 55.8%, Adj. EBITDA swings from -C$891K to +C$1.60M — yet the stock trades at 2.9x trailing Adj. EBITDA and 0.86x revenue. SNAPS's strategic US$9M investment at C$0.34/share (a 143% premium) signals the market is deeply mispricing this satellite infrastructure and government SATCOM business. ## Key statistics - Market Cap: C$4.7M - EV/Adj. EBITDA: ~3x - Revenue (FY2025): C$5.44M - Adj. EBITDA (FY2025): C$1.60M - Gross Margin: 55.8% - Rev. Growth (YoY): +37.1% ## Executive Summary Novra Technologies Inc. (TSXV: NVI) is a Winnipeg-based technology company providing satellite and IP-based broadband content distribution infrastructure to broadcast, government, and enterprise customers across more than 100 countries. Through its three operating entities — Novra Technologies, International Datacasting Corporation (IDC), and Wegener Corporation (51.6% controlled) — the Novra Group has over two decades of engineering heritage in satellite receivers, broadcast radio network infrastructure, digital cinema, and secure government SATCOM systems, with over 200,000 units shipped globally. We initiate coverage with a Speculative Buy rating and a 12-month price target of C$0.35, representing approximately 150% upside from current levels. FY2025 delivered a dramatic operating turnaround: revenue grew 37% to C$5.44M, gross margin expanded to 55.8%, and Adjusted EBITDA swung from a loss of C$891K to a gain of C$1.60M. At a C$4.7M market cap, the company trades at approximately 3x trailing Adj. EBITDA — a valuation that ascribes essentially zero strategic premium to an accelerating government defence business, a US$9M investment by AIoT strategic partner SNAPS at a 143% share price premium, and a growing software/SaaS recurring revenue base. ## Company Overview The Novra Group operates through three integrated business units sharing engineering resources, customer relationships, and global distribution: - International Datacasting Corporation (IDC) — Ottawa, ON: The Group's flagship technology subsidiary. IDC is a globally recognized provider of satellite broadcast solutions, including MAP Pro audio receivers for nationwide radio networks, data distribution receivers for government SATCOM platforms, and content management software. IDC has a multi-decade footprint in European broadcast radio and U.S. government secure communications, with growing activity in defence-adjacent sectors. - Novra Technologies — Winnipeg, MB: Hardware-focused business producing DVB and ATSC-compliant satellite receivers, IP encapsulators, and broadband communications products. Creator of the MISTiQ cloud-based content delivery platform (now in its third generation) and the new Cortex unified device management and IoT network control platform. - Wegener Corporation (51.6% controlling interest) — Atlanta, GA: Legacy broadcast solutions provider with North American broadcast customer relationships and ongoing integration into the Novra Group's unified engineering and product strategy. Novra continues to evaluate acquiring the remaining 48.4% minority interest. Revenue is split approximately evenly between products (54%) and services (46%), with the Americas generating 65% of revenue and EMEA contributing a strong 33%. The company served approximately 2,000 active customers as of FY2025. ## Investment Thesis — Five Pillars ### 1. FY2025 Turnaround Is Large and Real After a difficult FY2024 that saw revenue decline 47% to C$3.97M and Adj. EBITDA fall to a loss of C$891K, FY2025 represented a decisive reversal. Revenue grew 37.1% to C$5.44M, driven by the delivery of C$1.7M+ in backlogged orders carried into the year plus organic new orders. Gross margin expanded from 47.1% to 55.8% — driven by operating leverage on higher revenue, IRS Employee Retention Credits (ERC) received in 2025 that reduced staffing costs, and a favorable product/service mix. Adj. EBITDA turned from a loss of C$891K to a gain of C$1.60M, a C$2.5M swing. Q4 2025 alone delivered a 65.0% gross margin — the highest quarterly figure in recent memory — and net income of C$210K. The momentum is clear and the balance sheet improved sharply, with the third-party working capital ratio reaching 2.07:1 at year-end, up from 1.10:1 a year earlier. ### 2. Government and Defence: A Growing Anchor The most durable new growth vector for Novra is the expansion of government and defence activity across both IDC and Novra. Management highlighted in each quarterly filing through 2025 that defence organizations are stepping up investments in secure network upgrades and expansion, and that Novra is benefitting directly. Specific accomplishments in FY2025 include: completing a significant software development project to upgrade and modernize management and control software for a longstanding U.S. government SATCOM platform, transitioning from the legacy S300 to the next-generation S401 receiver (a project that strengthens Novra's embedded position for future hardware pull-through orders); receiving multiple significant U.S. government support contracts for long-running essential programs; and expanding the network of government-focused distribution partners in the U.S. and allied nations. The Novra MAP Pro Data GBS receiver is seeing growing adoption across U.S. government programs. Government SATCOM relationships are inherently sticky — once an architecture is embedded at the platform level, replacement cycles span years to decades. ### 3. Cortex, MISTiQ, and the Recurring Revenue Build Novra is deliberately pivoting its business model toward higher-margin, recurring software and services revenue. MISTiQ, the company's third-generation cloud-based broadcast delivery platform, is seeing growing traction and contract renewals among radio and video broadcasters migrating from satellite to internet delivery — a market that is expanding as the media industry seeks cost reduction and geographic reach. Cortex, launched in FY2025, is a new unified platform for centralized management of content distribution networks and large-scale IoT device fleets. Built on the MQTT protocol with TLS encryption, Cortex is designed for broadcast monitoring/control as well as commercial IoT use cases including asset tracking, agriculture, and industrial automation — giving Novra a foothold in IoT adjacencies well beyond its core broadcast market. Additionally, management flagged growing on-going security update service revenue from high-security government customers, and a new initiative targeting Unmanned Aerial Vehicle (UAV) communications modules developed with a strategic partner. Services represented 46% of FY2025 revenue and are growing the deferred revenue and customer deposit balances (C$1.3M and C$391K at Q3 year-end) that provide forward revenue visibility. ### 4. SNAPS: Strategic Capital and AIoT Optionality In 2024–2026 Novra entered into a transformative relationship with SNAPS Holding Company, an AIoT (Artificial Intelligence of Things) company building a vertically integrated ecosystem on proprietary wireless spectrum. SNAPS committed a total of US$9M in convertible financing. As of May 2026, US$3.7M has been received, and a new agreement for the remaining US$5.3M (to be provided by September 30, 2026) has been signed — all convertible at not less than C$0.34 per share. The C$0.34 conversion price represents a 143% premium to the current market price of C$0.14, providing strong independent third-party validation of Novra's strategic asset value. SNAPS cited Novra's global market reach, engineering excellence, SaaS/cloud proficiency, and wireless technology expertise as the drivers of their investment — attributes that align directly with SNAPS's strategy to build next-generation connected infrastructure. Subsequent to year-end, Novra received an additional US$3.2M (approximately C$4.4M) from SNAPS, materially strengthening the balance sheet. If the full US$9M converts at C$0.34, SNAPS will hold approximately 36.8 million Novra shares, making them the company's largest shareholder and aligning their interests firmly with long-term value creation. ### 5. Valuation: 3x Adj. EBITDA for a Growing, Profitable Business At C$0.14 per share and a C$4.7M market cap, Novra trades at approximately 2.9x its trailing FY2025 Adj. EBITDA of C$1.60M, and at less than 1x revenue. This is a remarkably compressed multiple for a technology company that has just demonstrated 37% revenue growth, a 55.8% gross margin, and a Adj. EBITDA margin of 29%. Even applying a steep small-cap and illiquidity discount, 8–10x Adj. EBITDA would be an unremarkable multiple for this business — implying a stock price of C$0.27–0.34 on current earnings alone, before any growth credit. The SNAPS conversion price of C$0.34 provides an independently derived anchor precisely in this range. Our base-case price target of C$0.35 implies roughly 8.4x trailing Adj. EBITDA — a level we consider still very conservative for a company with Novra's trajectory. ## Financial Summary | Metric | FY2023 | FY2024 | FY2025 | YoY Change | | Revenue (C$M) | $7.4M | $4.0M | $5.44M | +37.1% | | Products | — | $1.92M | $2.97M | +54% | | Services | — | $2.05M | $2.48M | +21% | | Gross Profit (C$M) | ~$3.5M | $1.87M | $3.04M | +62% | | Gross Margin | ~47% | 47.1% | 55.8% | +8.7 pts | | Operating Expenses (C$M) | — | $3.43M | $2.83M | -17.5% | | Net Income / (Loss) (C$M) | +$0.14M | -$1.68M | +$0.72M | NM | | Adj. EBITDA (C$M) | $0.85M | -$0.89M | +$1.60M | NM | | Cash & Liquidity (C$M) | — | $1.44M | $1.88M | +31% | Note: FY2025 net income includes C$660K in one-time accounts payable forgiveness income. Adj. EBITDA adjusts for non-recurring items and is the preferred measure of underlying operating performance. Post year-end, Novra received an additional US$3.2M (~C$4.4M) from SNAPS, materially improving the cash position. ## Quarterly Revenue Progression (FY2025) | Quarter | Revenue | Gross Margin | Adj. EBITDA | | Q1 2025 | $1.39M | 43.7% | $0.73M* | | Q2 2025 | $1.37M | 51.0% | $0.41M | | Q3 2025 | $1.21M | 63.7% | $0.06M | | Q4 2025 | $1.48M | 65.0% | $0.40M | | FY2025 Total | $5.44M | 55.8% | $1.60M | *Q1 Adj. EBITDA includes benefit from AP forgiveness of C$676K and ERC credits. ## Valuation We value Novra using both an EV/Revenue and EV/Adj. EBITDA approach. At a ~C$4.7M market cap, Novra trades at 2.9x trailing Adj. EBITDA and 0.86x trailing revenue — deeply discounted even before accounting for post-year-end SNAPS cash inflows that strengthen the net balance sheet position. Our base case applies 8x Adj. EBITDA — a modest multiple anchored by a comparable small-cap hardware/software technology peer set — to arrive at a price target of C$0.35. Notably, C$0.35 aligns closely with SNAPS's C$0.34 strategic conversion price, independently validating our estimate. | Scenario | Basis | EV | Price / Share (diluted) | vs. Current | | Bear Case | 4x Adj. EBITDA | $6.4M | C$0.17 | ~+20% | | Base Case | 8x Adj. EBITDA | $12.8M | C$0.28–0.35 | ~+100–150% | | Bull Case | 1.5x FY2026E Revenue | $9.5M+ | C$0.45 | ~+220% | | SNAPS Reference | Conversion price | — | C$0.34 | +143% | ## Key Risks - Revenue Lumpiness / Volatility (HIGH): Novra's hardware-driven revenue is project-based and inherently lumpy. The company itself cautions that "a large portion of quarterly revenues are generated from orders received during the quarter rather than from order backlog." Despite the FY2025 recovery, quarter-to-quarter swings remain significant — Q3 2025 Adj. EBITDA was only C$62K while Q1 and Q2 were much stronger. Investors must be comfortable with meaningful earnings volatility. - Customer Concentration (HIGH): The top 2 customers accounted for 34% of FY2025 revenue (~C$1.9M combined). The top 10 accounted for 66.5%. While Novra serves ~2,000 customers across 100+ countries, quarterly results can be heavily influenced by the timing of a small number of large orders. - SNAPS Dilution (MEDIUM): Full conversion of the US$9M SNAPS commitment at C$0.34/share would result in approximately 36.8 million new shares — growing total diluted shares from 33.4M to ~70M. At current prices, this would roughly halve the per-share equity value if no re-rating occurs. However, SNAPS's C$0.34 reference price implies a re-rating to approximately that level is the expected outcome, limiting dilution risk on a percentage-upside basis. - Secular Headwinds in Broadcast (MEDIUM): Traditional satellite broadcast distribution continues to face displacement by IP and streaming delivery. Novra's strategy of pivoting toward government/defence, cloud software (MISTiQ, Cortex), and IoT adjacencies is the correct response, but execution requires sustained R&D investment and sales development in new markets. - Credit Facility Risk (MEDIUM): The RBC credit facility (currently C$380K available) is subject to annual review. Non-renewal would limit financial flexibility, though the post-year-end SNAPS cash infusion substantially reduces the likelihood this creates a liquidity problem. - Micro-Cap Illiquidity (HIGH): At a ~C$4.7M market cap, Novra is one of the smallest TSXV-listed technology companies. Trading is extremely thin; any meaningful position cannot be exited without significant price impact. Not suitable for any but the smallest speculative allocation. ## Conclusion Novra Technologies (TSXV: NVI) has quietly delivered one of the more compelling turnaround stories in the TSXV technology universe. After a painful FY2024 revenue contraction, FY2025 saw revenue grow 37%, gross margin expand by nearly 9 percentage points to 55.8%, and Adj. EBITDA swing from a loss of C$891K to a gain of C$1.60M — a C$2.5 million operational improvement in a single year. The company is solidly profitable on an adjusted basis, has a healthy balance sheet (working capital ratio of 2.07:1 excluding related parties), and carries C$1.3M+ in deferred revenue and customer deposits providing forward visibility. Underpinning the recovery is a structural shift toward government and defence customers who are investing in secure satellite network upgrades — an accelerating market with sticky, multi-year contract dynamics. SNAPS's commitment of US$9M in capital at C$0.34 per share — a 143% premium to the current price — is perhaps the most direct signal: an AIoT-focused strategic investor has independently concluded that Novra's wireless technology expertise, global distribution, and engineering depth are worth nearly three times what the public market ascribes. At C$0.14 per share, ~C$4.7M market cap, and only 2.9x trailing Adj. EBITDA, the margin of safety is compelling and the upside is substantial. We rate NVI Speculative Buy with a 12-month price target of C$0.35. Position sizing should remain modest given extreme illiquidity and inherent lumpiness in project-driven revenue.